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Abstract
Objectives: To determine changes in prostate microparticle (PMP) concentrations in
men with prostate cancer (PCa) after digital rectal examination (DRE), after radical
prostatectomy (RP), and at follow-up.
Materials and Methods: 22 men were recruited before RP. Four blood specimens
were collected – baseline (specimen 1), post-DRE (specimen 2), immediately post-RP
(specimen 3), and follow-up (specimen 4). Pre- and post-DRE urine was collected
(Specimen A and B respectively). Flow cytometric analysis of biofluids was performed
with fluorescent-labeled antibodies against prostate-specific membrane antigen
(PSMA) and polysialic acid. Total MP (TMP) and dual positive (PMP) events per µl of
plasma or urine were recorded.
Results: Median TMPs from specimen 1 to 4 were 3 005 500, 1 600 600, 976 353,
and 3 951 400 events/µl, respectively (p<0.001). Median proportional PMPs
increased from 9.6% to 17.3% after DRE (p<0.001), to 25.7% (p<0.001) post-RP, and
decreased to 4.1% at follow-up (p=0.170). Urinary PMPs were unchanged after DRE.
Conclusions: Compared to baseline levels, proportional PMP events were
significantly increased following DRE, and further following RP.

Keywords: Prostate Cancer, Biomarker, Liquid Biopsy, Diagnosis, Risk Stratification,
Microparticle, Extracellular Vesicle, Exosome, Ectosome, Digital Rectal Examination
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Introduction
Prostate cancer (PCa) is the second most commonly diagnosed cancer among men
worldwide and accounts for approximately 6.6% of male cancer deaths (1). The large
majority of prostate cancers are indolent and remain organ-confined throughout
their natural history. A small proportion, however, are either aggressive ab initio or
become so at a later stage. Of men who have prostate cancer diagnosed, few will
have life-threatening disease. This is known from epidemiological data, but
discerning at an early stage which particular men will die from prostate cancer from
those that will not is very difficult.
Prostate-specific antigen (PSA), also called Human Kallikrein-3, was discovered and
characterised in the early 1980’s (2). Initial studies showed a positive correlation
between serum PSA levels and the presence of prostate cancer. It rapidly became,
and has remained, the standard biomarker for prostate cancer. Its clinical use
extends from screening to diagnosis, risk stratification, and disease monitoring. The
advent of the anatomic radical retropubic prostatectomy by Walsh in the 1980’s, the
improvement in technology for delivering radiation therapy, and then widespread
screening for asymptomatic disease with prostate-specific antigen (PSA) testing in
the early 1990’s all led to a massive increase in the number of men being treated
aggressively for localised prostate cancer. The widespread screening and treatment
that occurred from the early 1990’s onward resulted in a minor reduction in prostate
cancer mortality, at approximately 30-40% lower than in the pre-PSA era (3). The
reduced mortality rate, however came at a significant cost. There was substantial
over-investigation of asymptomatic men, since many would undergo unnecessary
prostate biopsy and other investigations. It also led to aggressive treatment of men
with latent prostate cancer who were at low risk of progressive or fatal disease. This
marginal benefit of PCa screening suggested by epidemiological studies was
confirmed in several randomised controlled trials, most notably the European
Randomised Study of Screening for Prostate Cancer (ERSPC). As a result of these
trials, in 2012 the United States Preventative Services Taskforce (USPTF)
recommended against routine screening for PCa (4). They cited a high risk of men
being “overdiagnosed” and “overtreated”. Overdiagnosis refers to the diagnosis of

2
cancer that would otherwise never have been symptomatic, and overtreatment is
when men undergo radical therapy for disease that would never have been life
threatening. The most recent analysis of the data from the ERSPC suggests that to
save one man from death due to prostate cancer, 781 men need to be offered
screening, and 27 additional cancers need to be diagnosed (5). After the
recommendation by the USPSTF, many other healthcare organisations followed suit,
and these recommendations were subsequently taken to heart among primary care
providers. There is much evidence that fewer men were indeed screened in the
years subsequent to the 2012 recommendations, and an upward stage migration in
PCa has occurred since that time (6). This presumably indicates delayed diagnosis.
There is therefore an apparent paradox when it comes to screening for PCa. On the
one hand, it is a common disease and a common cause of death among men. Early
detection is possible, and several effective curative treatments are available. On the
other hand, however, evidence from observational data and from randomised trials
has shown limited benefit to screening of asymptomatic men, with a high rate of
overinvestigation, overdiagnosis, and overtreatment.
There are several underlying factors that explain this apparent paradox. The first is
that although the mortality from prostate cancer is high, the prevalence of PCa in
middle aged and elderly men in the population is extremely high. While men have a
3-6% chance of dying of prostate cancer, men over 60 years old have a greater than
50% chance of harbouring at least a small focus of prostate cancer (7). So for any one
man with prostate cancer, the chance of dying of the disease is low. There has
recently emerged the concept of “clinically significant” PCa, which excludes the small
volume, low grade cancers that are unlikely to be immediately dangerous. Secondly,
screening for prostate cancer currently utilises a combination of two poor tests.
These are serum PSA and transrectal ultrasound-guided (TRUS) biopsy. In most
series, only 25-40% of men with abnormal PSA levels will have a positive biopsy.
Many of the cancers diagnosed are clinically insignificant, while up to 20% of
clinically significant cancers are missed due to the random nature of the biopsy. The
histological grade of PCa - the Gleason score - is currently the most accurate
predictor of disease behaviour, but the transrectal biopsy necessary to obtain the
prostate tissue is invasive and carries the risk of complications. Common side effects
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of transrectal biopsy include pain, rectal and urethral bleeding, worsening of lower
urinary tract symptoms, and a temporary worsening of erectile function (8). Less
common, but potentially more serious is post-biopsy sepsis. Up to 1.7% of men are
hospitalised for infectious complications following prostate biopsy (8). In the ERSPC
trial, there were 28 biopsies performed for every 100 men screened (5).This means
that many men who opt for PSA screening will undergo a lengthy, costly, and
potentially morbid process of investigation, and then turn out not to have clinically
significant PCa. The third reason that screening has not worked well is that a much
higher proportion of men undergo curative treatment for prostate cancer than
would be expected to die of the disease. Another estimate from the ERSPC data is
that an additional 17 cases of prostate cancer need to be diagnosed in order to save
one life. The majority of those 17 patients would undergo radical treatment,
indicating the high degree of overtreatment. This treatment is usually radical
prostatectomy (RP), external beam radiotherapy (EBRT), or interstitial brachytherapy
(BT).
These treatments all have significant side effects, including urinary incontinence,
urinary obstruction, erectile dysfunction, and bowel dysfunction. They also place a
burden of time, anxiety, pain, and discomfort. The financial impact of these
investigations and treatment is significant. An analysis from 2006 estimated the total
cost per patient diagnosed with prostate cancer was in excess of US$18,000 from
diagnosis to four years of follow-up (9). The number of men undergoing these
treatments has decreased progressively over the last 15 years as it has been
recognised that men with low risk prostate cancer benefit less from curative
treatment, leading to the increased uptake of Active Surveillance (AS) in that
population. This strategy has now been universally accepted as a way to reduce
unnecessary treatment of PCa. However, only 20-30% of men with newly diagnosed
PCa will meet strict criteria for AS, and up to 50% of those men will proceed to
curative treatment within a few years. The follow-up regimens for AS are also
relatively onerous on the patient. This leaves the majority of men diagnosed with
PCa as non-candidates for AS, the majority of whom will also not die of PCa even if
left untreated. They would thus still be both overdiagnosed and overtreated for PCa.
The obvious problem is the imperfection of current methods of risk stratification.
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Because of a large degree of uncertainty, healthcare providers err quite heavily on
the side of overtreatment.
These clinical challenges highlight the current need for a better biomarker for
prostate cancer. Currently, PSA is used for screening, risk stratification,
prognostication, and follow-up. Many novel biomarkers have been brought to
market since the advent of PSA, but all of them have only been able to augment the
role of PSA, and not replace it entirely.

Extracellular vesicles, also known as “microparticles”, represent one of the most
promising new frontiers for biomarker research. They are subcellular cell-derived
vesicles that carry membrane antigens of their parent cells and carry specific protein
and genomic cargo. While their existence has been recognised for several decades,
the technology to accurately quantify and to characterise microparticles has been a
limiting factor up until relatively recently. Publications citing the term “extracellular
vesicle” have increased 10 fold over the last 15 years, which illustrates the rapidly
increasing interest in the field. It is now recognised that almost all cells in the body
release extracellular vesicles. Many of which find their way into the circulation, and
this is also true of the prostate (10). Circulating concentrations of microparticles
have been shown to be increased in patients with cancer (11). Microparticles or
extracellular vesicles originating from the prostate that are detectable in the blood
are a promising non-invasive biomarker for prostate cancer.
The study that forms the basis of this dissertation is an analysis of prostate
microparticles in the blood and urine of a cohort of men undergoing radical
prostatectomy for localised prostate cancer. The aim of the study was to determine
whether a digital rectal examination would increase the levels of microparticles in
the blood or urine. The first chapter is a literature review that reviews the currently
available biomarkers for prostate cancer, as well as extracellular vesicles, with a
focus on prostate microparticles. The second chapter deals with technical details
related to specimen collection, sample preparation, and flow cytometry. The third
chapter reports the findings of our study examining PCMPs in the serum of men
before and after DRE, as well as immediately after prostatectomy and at short term
follow-up. The fourth chapter reports the findings of the study on PCMPs in the
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urine of the same cohort of men before and after DRE prior to radical
prostatectomy. The fifth chapter is a general discussion around the issues raised and
hypotheses generated.

1

Chapter 1: Literature Review
This dissertation is focused on the role that blood borne microparticles may play
clinically as a novel biomarker for prostate cancer. The literature review therefore
has two parts. The first covers the currently available biomarkers for prostate cancer,
with special emphasis on their test performance characteristics for diagnosis and risk
stratification. The second part aims to give a general overview of the literature on
microparticles, as well as a more detailed account of what is known about
microparticles and prostate cancer.

Methods
A literature review was performed using the Medline database and Google Scholar.
For the section on prostate cancer biomarkers, the search terms used were
“prostate cancer”, “biomarkers”, “diagnosis”, “risk stratification”, “imaging”, and
“active surveillance” in varying combinations. For the microparticle section, the
terms “microparticle”, “extracellular vesicle”, “endosome”, “exosome”,
“prostasome”, and “oncosome” were used. The search was limited to original peerreviewed articles published in English since 2000. Articles were screened on title and
abstract. Selected references from applicable articles were also looked up where
appropriate. Articles on microparticles that dealt with the prostate and prostate
cancer were all reviewed fully, while articles specific to other organ systems, general
reviews, or technical aspects were reviewed on a more selective basis.

Current Biomarkers for Prostate Cancer
The term “biomarker” is a portmanteau of the term “biological marker”. There are
myriad and sometimes conflicting definitions. The National Institutes of Health
Biomarkers Definitions Working Group defined a biomarker as “a characteristic that
is objectively measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic intervention”
(12). In the context of prostate cancer, this broad definition would incorporate blood
tests, urine tests, imaging investigations, and histological investigations. Since the
prostate cancer microparticle test would seek to fill the role of a diagnostic and risk
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stratification test, this literature review has been limited to currentcommercially
available blood and tissue biomarkers, and to a more limited extent, currently
available imaging modalities.

Prostate-Specific Antigen
The prototypical biomarker for prostate cancer is prostate-specific antigen (PSA).
PSA is a normal exocrine secretory product of the prostate gland. It is a 33 kilodalton
serine protease, and is a member of the human kallikrein family. Its physiological
function it to liquefy the seminal coagulum (13). PSA was identified in human semen
in the 1970’s by various investigators, most notably by Richard Ablin in Buffalo, NY
(2). At that time, the only available biomarker for prostate cancer was prostate acid
phosphatase (PAP) which was only a reliable marker for metastatic disease (14). The
scientific work that would bring PSA to the fore was done by Wang and Chu at the
Roswell Park Memorial Institute, with their first of a series of important papers being
published in 1979. They purified the protein, characterised it, and suggested it as a
biomarker for prostate cancer. Based on their initial studies and those of Stamey et
al., PSA was initially patented and approved by the FDA as a tool to monitor disease
progression and response to treatment in men undergoing radical prostatectomy,
radical radiotherapy, androgen deprivation therapy, and treatment of castrateresistant disease (15). In the early 1990’s it was also found to be useful for screening
asymptomatic men for PCa (16). This new clinical indication led to the massive
increase in prostate cancer screening seen in most developed countries, and the
subsequent increase in treatments for localised disease (17).
In addition to disease monitoring and screening, PSA was also incorporated into
methods of risk stratifying men with apparent localised disease. The system
proposed by D’Amico et al. in 1998 used pre-treatment PSA together with Gleason
sum on prostate biopsy and findings on digital rectal examination to stratify men
into low, intermediate, and high risk groups to predict their chance of biochemical
recurrence after local treatment (18). This tool was subsequently validated in
multiple external cohorts and quickly became the standard method of risk
stratification, as well as the basis for newer risk classification systems (19). As it
became more widely recognised that localised prostate cancer was being
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overtreated, the strategy of active surveillance was developed in the late 1990’s and
early 2000’s. Again, PSA was used in all large series as one of the primary indicators
of disease progression, with a rise either prompting further investigation, or
triggering treatment (20,21). This newer use for PSA as a biomarker is a direct
extension of its role in risk stratification.
PSA testing has proven to be very accurate in detecting recurrent prostate cancer
after surgery (22). It is also fairly reliable for recurrence of cancer after radiotherapy
and disease progression in metastatic PCa. However, PSA performs poorly for other
indications, most notably screening and risk stratification. For screening purposes,
there is not a cut-point below which PCa is certain to be absent, or a reasonable cutpoint above which cancer is certainly present. For instance, at all PSA cut-points,
there will be patients with prostate cancer that will be missed (Type 2 error) and
there will be a significant number of patients that have been incorrectly “flagged” as
having prostate cancer (Type 1 error). The most widely used value for “normal PSA”
is ≤4.0 ng/ml. The positive predictive value at this level (≥4.0 ng/mL) is only 25-40%
(23). Also, more than 20% of the men thus diagnosed will have clinically insignificant
cancer. Data from the Prostate Cancer Prevention Trial (PCPT) suggested that, in
order to achieve a sensitivity of 80%, the PSA threshold would need to be reduced to
1.0 ng/ml, but at that cut-point, the false-positive rate would be above 60% (24).
Using data from the Prostate Cancer Prevention Trial, Thompson et al. reported an
area under the receiver operating curve (AUC) of 67.8% for PSA alone (25). 20% of
men meeting very low risk criteria have “significant disease” at RP (26).
Two of the refinements made in PSA testing since its introduction are the
calculation of PSA density and the measurement of free PSA. PSA density is a
measure of the serum PSA level as a proportion of the prostate volume. This corrects
somewhat for the effect of prostate size and makes the test more sensitive for the
detection of cancer (27). While the PSA density improves prediction of cancer better
than PSA alone, the shortcoming is that it generally requires TRUS to accurately
assess prostate volume, which is impractical to do for all patients in a screening
situation. The role of PSA density in risk stratification is less clear.
Free PSA is a measure of the concentration of serum PSA that is not bound to
plasma proteins. It is absorbed from the glandular lumen after inactivation of mature
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active PSA, and is therefore underrepresented when a high serum PSA is driven by a
malignant process with disordered glands (28). A high proportion of free PSA is
indicative of a lower likelihood of malignancy, and vice versa. Free PSA is
recommended in the “grey zone” of PSA 2.5-10 where it can sometimes assist with
decision-making during screening. Unfortunately, it also represents a spectrum of
risk, with the majority of patients remaining in a new grey zone somewhere in the
middle. A large meta-analysis of studies on free PSA calculated an AUC of 0.70 for
the detection of cancer, which is only marginally better than total PSA alone (29).
Based on extrapolation from external data, percent free PSA was included in an
updated version of the PCPT risk calculator, but it was not found to be a particularly
strong discriminator between high grade, low grade, and no prostate cancer (30). A
similar study using a subset of pre-screened men in the ERSPC found that %fPSA had
no predictive power (31). As with PSA density, there is no clearly established role for
free PSA measurements in risk stratification.
Other attempts at improving PSA testing in clinical practice include differing age
and race cutoffs, PSA changes over time (PSA doubling time or PSA velocity), and
baseline PSA at a younger age, but these modifications have not found a firm place
in clinical practice. To diagnose prostate cancer, a histological diagnosis is typically
made by means of a random multiple core TRUS biopsy. By its random nature,
transrectal biopsy misses up to 25% of cancers (32), and can underestimate tumour
extent and grade by 30%, thus further reducing the usefulness of PSA as a screening
test (33,34). These same shortcomings of the random TRUS biopsy approach also
reduce the accuracy of risk stratification in prostate cancer.
These issues underscore the major deficiencies of PSA as a clinical tool, and the
need for better methods of screening asymptomatic men and risk stratifying those
with an established diagnosis of prostate cancer.

5

Non-invasive biomarkers

PCA3
Prostate Cancer Antigen 3 (PCA3) was first described by Bussemakers et al. in 1999
(35), where it was initially referred to as DD3. It is a gene that is highly overexpressed
in prostate cancer tissue – up to 60 times higher than in benign prostate tissue (36).
Hessels et al. tested the concentration of PCA3 mRNA in first voided urine after a
vigorous prostate massage in 108 men with raised PSA values prior to prostate
biopsy. This was expressed as a ratio of PCA3 to PSA mRNA concentrations. The test
performed with an AUC of 0.717 (0.58–0.85), which was better than that of serum
PSA. The ProgensaTM PCA3 assay (Gen-Probe Inc, San Diego, Calif) was granted FDA
approval in 2006, becoming the first prostate biomarker to be approved since the
approval of PSA 20 years earlier.
The initial results were validated in numerous other cohorts, generally producing
AUC values of above 0.690 (37,38). At a cut off value of 50 x 10-3, the sensitivity of
the test was found to be 0.69, while maintaining a relatively modest specificity of
0.79. Hansen et al. incorporated the PCA3 score into a pre-biopsy nomogram that
also utilised age, PSA, prostate volume, and DRE findings. On univariate analysis,
they found that PCA3 was the strongest single predictor of a positive biopsy. By using
this nomogram, the authors concluded that 55% of unnecessary biopsies could be
avoided at the cost of missing less than 2% of high grade cancers (39). A study
performed at the National Cancer Institute prospectively enrolled 859 men prior to
scheduled prostate biopsy and performed a PCA3 test (40). For biopsy naïve men, a
PCA3 score of >60 gave a PPV of 80% for detection of any cancer, while for men
undergoing repeat biopsy, a PCA3 score of <20 gave a NPV of 88%. While the latter
indication might be clinically useful, the sensitivity of PCA3 >60 for first time biopsies
was only 0.42. When used in combination with the PCPT risk calculator, the AUCs for
detecting high grade disease were 0.78 and 0.79 for initial and repeat biopsies,
respectively.
PCA3 has also been evaluated in the context of risk stratification. Ploussard et al.
studied 106 men with low risk PCa who underwent RP with the intention of using
the PCA3 test to determine eligibility for AS (41). PCA3 score >25 was significantly
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associated with a more than threefold higher risk of having a tumour volume of >0.5
cm3. However, it did not accurately which patients would have extraprostatic disease
or an overall unfavourable pathology (Gleason pattern ≥4, T3+, N+, or tumour
volume >0.5 cm3). Furthermore, the PCA3 did not seem to add much more value
than the so-called Epstein biopsy criteria which are aimed at identifying low grade,
low volume disease. The authors concluded that while PCA3 might be incorporated
into an AS selection protocol, it could not be used as a sole prognostic variable
among low risk men. The implication of their statement is that AS might be advised
against in the setting of a high PCA3, even if other factors suggest very low risk
disease, although this conjecture was not clear from their reported analysis. Two
studies have shown that PCA3 score is an independent predictor of multifocal
disease among men undergoing radical prostatectomy (42,43).
In the 13 years since this test was first described, usage of the PCA3 test has
remained fairly limited in most centres, possibly due to increased cost and/or the
need for a prostate massage prior to testing.

TMPRSS2:ERG
Transmembrane protease, serine 2 (TMPRSS2) is a serine protease that contains a
type II transmembrane domain and is expressed in prostatic basal cells and in
prostate carcinoma (44). It is encoded by the TMPRSS2 gene.
In 2005, Tomlins et al. described abnormal fusion of the TMPRSS2 gene to various
transcription factors of the ETS family, most commonly ERG and ETV1, in prostate
cancer cells (45). This was postulated to be an oncogenic mechanism, whereby a
cell’s attempted expression of TMPRSS2 would lead to overexpression of these
transcription factors. It was subsequently found that approximately 50% of screendetected prostate cancers had TMPRSS2:ETS fusions, and that ERG accounted for
approximately 90% of such chromosomal rearrangements (46). Detection of either
the gene fusion itself or the resultant truncated ERG protein is almost 100% specific
for PCa. The protein product is not detectable in the blood or urine, but
TMPRSS2:ERG mRNA can be detected in the urine, which has led to its use as a noninvasive biomarker. In an independent cohort, Esgueva et al. identified
TMPRSS2:ERG fusions in 37% of 540 cases of PCa (47).
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The group that first developed this urine PCR test then developed a urine test that
utilised the same technology as the commercially available PCA3 test. The collection
also involved a first catch urine sample after a vigorous DRE. This test is sometimes
referred to as the T2 score, and is also reported as a ratio of the mRNA to that of PSA
mRNA. It was quickly realised that the very high specificity, but low sensitivity of the
TMPRSS2:ERG test could be coupled to the PCA3 test which had a higher sensitivity
at a lower specificity. A prospective multicentre Dutch study performed PCA3 and T2
tests on 497 men prior to prostate biopsy (48). In that study, addition of PCA3 to the
ERSPC risk calculator improved the AUC for positive biopsy from 0.799 to 0.833. With
the addition of T2, the AUC improved further to 0.842. T2 score was also a predictor
of Gleason score, with OR 7.16 (2.54-20.15). Among the 61 patients in the cohort
who underwent RP, the T2 score correlated with extraprostatic extension – with OR
4.91 (1.13-21.98) – but not with Gleason upgrading or seminal vesicle invasion.
Investigating the combination of PCA3 and T2 scores as a risk stratification tool, Lin
et al. tested the urine of 387 men in the Canary Prostate Active Surveillance Study
(49). The aim was to determine whether the tests could predict higher volume or
pathological upgrading on repeat prostate biopsy. While the markers did correlate
with biopsy findings on repeat biopsy, neither marker alone or a combination of the
two added any statistically significant improvement in prediction over PSA alone. In a
similar study, Cornu et al. performed TMPRSS2:ERG and PCA3 on men on active
surveillance prior to a second biopsy, but with additional genotyping tests (50). They
too found that the results of the urine assays did no better than PSA or PSA density
at predicting pathological upgrading or increased tumour volume.
The combination of PCA3 and T2 scores is now commercially available as the MiProstate Score, or MiPS. This test combination was investigated as a tool to reduce
unnecessary repeat biopsy by Merdan et al. (51). Among men with raised PSAs and
an initial negative biopsy, at thresholds for PCA3 and T2 of ≥25 and ≥10, respectively,
biopsies could be reduced by 54.4% and 63.2%, respectively. The calculated cost of
this reduction in biopsies was a reduction in 10-year cancer-specific survival of only
0.9% and 1.4%, respectively.
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[-2]proPSA and PHI
[-2]proPSA was first described by Mikolajczyk et al. in 2001 (52). PSA is produced as
a proenzyme that has a 17 amino acid leading sequence. Cleavage of this protein
gives rise to proPSA, which has an additional 7 amino acids at the N terminal
compared to normal PSA ([-7]proPSA). Mature PSA is then generated in the glandular
lumen by cleavage of those 7 amino acids by Human Kallikren 2 (hK2) and to a lesser
extent hK4 (28). Other proteolytic enzymes can cleave the N terminal amino acids in
other positions, leading to generation of inactive [-2] and [-5] proPSA. These
isoforms of the PSA enzyme occur at higher concentrations in prostate cancer,
presumably because of less exposure to hK2 in the glandular lumen. As mentioned in
the section on PSA above, active PSA becomes inactive after it undergoes “nicking”
in any of three different locations. It then also circulates as free PSA. This process is
more likely to occur in benign tissue. The ratio of free PSA to the [-2]proPSA has
turned out to be more useful than [-2]proPSA concentrations alone in distinguishing
benign from malignant causes of a raised PSA.
The “prostate health index” (phi) is a formula that utilises the [-2]proPSA level in
combination with the free and total PSA values (phi = p2PSA/fPSA x tPSA½) (53). In a
prospective study by Catalona et al., a cohort of men with PSA values in the range of
2-10 ng/ml had phi determined prior to first biopsy (54). The test achieved an AUC of
0.703 for the detection of cancer overall, and an AUC of 0.724 for distinguishing
Gleason 7 and above from benign disease or Gleason 6. The clinical usefulness might
be limited due to the fact that 26.1% of men with a phi score of 0-24.9 had Gleason
≥7 disease. In a study on samples from two sites of the ERSPC, Jansen et al., 2010
(53) did not find the levels of p2PSA or phi before biopsy to be significantly different
between men with Gleason ≤6 vs ≥7 disease. Guazonni et al., 2011 also found that
%p2PSA and phi improved the diagnostic accuracy prior to biopsy, with AUC’s of
0.756 and 0.757, respectively (55). However, they did not improve prediction of
Gleason score. The same group analysed p2PSA and its derivatives in 350 men
undergoing RP. They found that %p2PSA and phi were both significantly higher in the
presence of pT3 disease, Gleason ≥7, and Gleason upgrading (56). Levels were lower
in men with tumour volume <0.5 ml. The main advantage of this study was that it
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was correlated with operative histology rather than with the results of TRUS biopsy.
However, this was not in a screening population, since most men were intermediate
or high risk. The group developed multivariate predictive models for T3, Gleason ≥7,
Gleason upgrading, and low volume disease that included other clinical and
pathological variables (such as age, clinical stage, PSA, biopsy results). The addition
of %p2PSA and phi improved AUCs by up to 6%, with phi being slightly superior to
%p2PSA. The best AUC was for predicting low volume disease (0.875). Of particular
pertinence for an AS setting is the Gleason upgrading from 6 to ≥7. AUCs for
predicting upgrading were 0.696, 0.747, and 0.753 for the base model, the model
including %p2PSA, and the model including phi, respectively. Again, the other
characteristics of this population (prostate volume, volume of cancer on biopsy, PSA,
clinical stage) might limit the applicability. Although the addition of %p2PSA and phi
significantly improved risk assessment, the benefit was marginal and there seems to
be a large tradeoff between sensitivity and specificity at all cutpoints.
Makarov et al. (2009) performed a retrospective analysis of sera of 71 men on AS
(57). 39 men in that cohort subsequently progressed to radical treatment, either
because of higher Gleason grade or higher tumour volume on prostate biopsy. 32 of
those men retained favourable biopsy criteria. Retrospective measurement of
%p2PSA showed higher values at diagnosis in men who subsequently needed
treatment for PCa. Hazard ratio for progression was 2.53 (1.18-5.41) p = 0.02.Using
the same cohort of 71 men, Isharwal et al. also measured the prostate health index
(phi) as well as the DNA content of their biopsy specimens using the AcuCyte imaging
system. In that study, the phi performed equally as well as the %p2PSA, with AUCs of
0.625 and 0.616, respectively. Ferro et al. obtained %p2PSA, phi, and PCA3 on a
cohort of 251 men undergoing first prostate biopsy. Both the phi and the PCA3
scores offered significant improvement over PSA alone, free PSA, %free PSA, and
p2PSA in predicting positive biopsy. With specificity fixed at 0.9, the sensitivities of
phi and PCA3 were similar at 0.36 (0.13-0.62) and 0.32 (0.04-0.49), respectively.

4Kscore
The 4Kscore® (OPKO Health, NJ) is a test named for the four kallikreins that are
measured, namely total PSA, free PSA, intact PSA, and hK2. Using a proprietary
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algorithm, the values are combined with clinical factors such as age and previous
biopsy history to estimate the risk of a high grade disease at biopsy (58).
In a cohort of men with PSA 3-15 undergoing first time biopsy, Nordstrom et al.
compared 4Kscore and phi to a base model of age and PSA alone in predicting
positive biopsy and high grade (Gleason ≥7) tumour (59). Both were superior to the
base model by very similar margins. For predicting a positive biopsy, AUCs for
4Kscore and phi were 0.690 and 0.704, respectively. For high grade cancer, AUCs
were 0.718 and 0.711, respectively. Both are simple blood tests that do not require a
vigorous DRE. The authors concluded that 29% of biopsies could be avoided at a cost
of initially missing 10% of high grade cancers.
A similar study in a larger cohort, reported by Parek et al., aimed to assess the
4Kscore in predicting Gleason ≥7 PCa (60). The 4Kscore showed an AUC of 0.820
which was significantly better than the PCPT risk calculator. The authors calculated
that 30-58% of biopsies could be avoided, while missing 1.3-4.7% of Gleason ≥7
cancers. Vickers et al. examined the use of the 4Kscore among men “outside of the
diagnostic gray zone” – with PSAs of 10-25 ng/ml or positive digital rectal
examination in a large cohort (61). Their findings suggested that its use in this
population could still reduce biopsy rates by 20% while only missing 3% of high grade
cancers. Vedder et al. investigated the added value of PCA3 and the 4Kscores in men
undergoing repeat screening in the fourth round of the Dutch ERSPC screening arm
(31). While the 4k score was slightly better than PCA3 at predicting a positive biopsy
among men with raised PSAs, the PCA3 performed better overall in a multivariable
model. All differences were small, indicating that the tests performed similarly but
also that the added benefit of these ancillary tests in that setting was relatively
minimal. A recent meta-analysis by Voigt et al. confirmed a net improvement in
diagnostic ability above PSA of 8-10%, and their cost analysis suggested that its
widespread use could potentially result in annual savings of $1 billion in the USA
(62).
While the majority of research on the 4Kscore has been performed in the context of
pre-biopsy prediction of positive biopsy and high Gleason tumours, there is some
data on the ability of the 4Kscore to risk stratify men known to have cancer. Carlsson
et al. studied a cohort of 392 men with PCa from the Rotterdam arm of the ERSPC

11
who underwent RP between 1994 and 2004. They found that 4Kscore accurately
predicted significant disease (Gleason ≥7 or volume >0.5 cm3) on final pathology,
most markedly in the low and very low risk groups (63). The AUC was calculated at
0.81. Punnen et al. analysed pathological findings at RP among 141 men who had
had a 4Kscore prior to their initial prostate biopsy (64). While the score correlated
with the histological grade, tumour volume, and extraprostatic disease at RP, its use
did not improve upon established clinical risk stratification such as D’Amico
classification. Part of the discrepancy between the results of this study and that of
Carlsson et al. is possibly due to lower numbers studied, but is also likely to be
affected by differences in clinical characteristics. The former study included a much
larger proportion of men with low risk disease, while the latter was composed
mainly of men known to have at least intermediate disease. This highlights the
potential clinical use of the 4Kscore test in selecting out low risk men for radical
treatment rather than selecting intermediate risk men for surveillance.
It is known that PSA level at a young age is predictive of likelihood of increased PCaspecific mortality later in life (65). Stattin et al. investigated the use of the 4Kscore to
sub stratify men in at age 50-60 yrs with high baseline PSA values (66). They found
that half of men with PSA values >2 ng/ml could be regarded as low risk based on
their 4Kscore, with a risk of metastatic PCa at 15 yrs of less than 1%.
The 4Kscore has yet to receive approval from the FDA.

Newer Non-Invasive Biomarkers
ExoDx Prostate Intelliscore
The ExoDx™ Prostate (IntelliScore) (Exosome Diagnostics, Waltham, MA), also called
the EPI score, is an assay measuring three different exosomal proteins in a first void
urine sample. Unlike the PCA3 test, there is no need for a DRE prior to taking the
sample (67). The test is intended to predict Gleason ≥7 cancer in a pre-biopsy
setting. Development was on a training cohort of 499 patients with PSA values of 2
to 20 ng/ml, and validation then performed in a multi-institutional cohort of 1064
patients. For tumours of Gleason score ≥7, the negative predictive value of the test
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was 91.3%, with a sensitivity of 91.9% (67). Using the test, 37% of biopsies could be
avoided at the cost of missing 13% of Gleason ≥7 tumours. A poster presentation at
the AUA 2017 meeting reported on a study analysing EPI scores in a pre-RP cohort.
The EPI scores correlated with pathological stage and Gleason/ISUP grade. Among
men who had pathological upgrading from a pre-RP biopsy grade of ISUP 1 (Gleason
6), the EPI score was significantly associated with upgrading at RP (p<0.001) (68).
This suggests that the test may have some utility in selecting men for AS, or for
subsequent monitoring on AS. However, the test has not yet been studied in an
active surveillance population.

Circulating RNA
There has been much recent interest in circulating genetic material as biomarkers
for PCa. Non-coding RNA (ncRNA) are segments of RNA that are transcribed from
non-coding DNA and are not transcribed into proteins, but are nevertheless
important for normal cellular functions (69). Alterations in ncRNA regulation also
have a role in tumour biology. ncRNA can be subdivided based on size into long noncoding RNA (lncRNA) and small non-coding RNA (sncRNA). There is evidence that
certain lncRNAs regulate certain cellular processes, including proliferation,
differentiation, or apoptosis (69). The most well-known lncRNA PCa biomarker is
PCA3, which has been discussed above. Another promising lncRNA marker is
SchLAP1 which was found to predict 10 year metastasis with an odds ratio(OR) of
2.45 (1.70–3.53) when identified in PCa tissue after RP (70). Although this OR was
slightly better than that of the Gleason score at final pathology, it is not clear what
the additive benefit of this marker might be. There are several other lncRNA
sequences that correlate to the presence of prostate cancer.
MicroRNAs (miRNAs) are a subtype of sncRNA, and have recently received more
research attention in the biomarker space, possibly due to their increased
accessibility in the blood and urine. miRNAs are small (17-27 nt) single stranded RNA
molecules that bind to non-coding regions of messenger RNA, thereby down
regulating gene expression. Not only are miRNAs integral to normal cellular
functioning, they can also be phenotypic markers of malignant cells (71). The
majority of circulating miRNA is found within extracellular vesicles, but miRNA is also
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present free in the circulation, bound to ribonucleoprotein complexes, or within
liposomes (72). Multiple studies have shown that at least 61 different miRNAs have
altered expression in PCa cells, and at least 19 of those show some correlation to
prognostic indicators such as Gleason score or metastasis (71). The studies on miRNA
in PCa are thus far only preliminary in nature (73). There is much promise that large
panels of miRNA will be commercially available in the future, but significantly more
clinical study is still required.

DNA hypermethylation
DNA hypermethylation of various PCa-promoting genes is an important epigenetic
mechanism in carcinogenesis and cancer progression. Hypermethylated GSTP1,
T1G1, EDNRBRASSF2, HIST1H4K, TFAP2E, and others have been shown to correlate
with the presence of PCa (74,75). The presence of hypermethylated genes in benign
prostate tissue has been used as an indicator of occult malignancy elsewhere in the
prostate. This forms the basis of the ConfirmMDx test that is performed on FFPE
specimens from prostate biopsy to predict the likelihood of a positive repeat biopsy
(see below).
These same hypermethylated genes can also be detected by PCR in the blood or
urine. Zhao et al. analysed 8 DNA methylation biomarkers in the urine of 153 men
on AS (76). APC, CRIP3, GSTP1 and HOXD8 were identified as predictors of disease
reclassification on repeat biopsy, with OR of 2. 559 (1.257-5.212). They found that
these markers were superior to clinical criteria such as PSA values or findings on
initial biopsy. There is no commercially available test at this time.

Proteomics, Metabolomics, Autoantibodies
Proteomics and metabolomics are fields in which proteins in the serum and urine
are detected and quantified, generally using mass spectrometry. Protein signatures
have been used make predictions on biochemical recurrence after treatment or
response to chemotherapy (77). Prostarix (Metabolon Inc, Morrisville, NC) is a
commercially available test that uses tandem liquid chromatography and mass
spectroscopy to quantify 4 different metabolites in post-DRE urine (78). It is designed
to predict chance of a positive first or repeat prostate biopsy. In the initial study, the
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AUC for detection of cancer was a modest 0.64. When combined in a logistic
regression with other clinical parameters, such as age, PSA, and TRUS-measured
prostate volume, the AUC increases to 0.78.
Another new avenue of biomarker research is autoantibodies to prostate cancer
specific antigens. One team has shown that antibody responses to PRDX6 and
ANXA11 are found in greater concentrations in PCa patients (79).

Circulating Tumour Cells
Detection of malignant cells in the circulation is possible with specialised
commercially available flow cytometry systems, most commonly the CellSearch®
system (Janssen Diagnostics, Raritan, NJ). Among men with metastatic prostate
cancer, the number of circulating tumour cells (CTCs) correlates with PSA values,
metastatic burden, time to progression, response to treatment, and overall survival
(80–82).
More recently, molecular analysis of genetic material within CTCs has been the
subject of research. The most notable is the identification of mRNA for a mutated
version of the androgen receptor, named AR-V7. Positivity for this variant predicts
poor response to newer generation androgen inhibitors such as Abiraterone and
Enzalutamide (83). This biomarker could prove useful in treatment selection for men
with metastatic disease. Other studies have analysed CTCs for the presence of
abnormalities such as PTEN loss and TMPRSS2:ERG fusion, with promising results
(84).

Tissue biomarkers
Many genetic abnormalities can be identified using immunohistochemical
techniques. Examples in PCa include p53, Bcl-2, MDM2, Ki-67, and AMACR and loss
of PTEN, and these have all been shown to correlate with worse outcomes, such as
higher biochemical recurrence rates after RP (85). Unfortunately, measurement of
the degree of staining of these markers is somewhat subjective and there is
significant variation between laboratories and between different commercially
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available antibodies. This makes these methods difficult to investigate as viable
biomarkers.
On June 13, 2013, the US Supreme Court ruled that naturally occurring genes could
not be patented, thus invalidating over 4,300 existing gene patents. This has been a
major factor leading to the proliferation of genetic panels used to risk stratify
patients for various types of cancer. Additionally, improvements in technology and
reductions in cost have made genetic testing more accessible and affordable.
Currently commercially available genetic tissue biomarkers for prostate cancer test
for somatic mutations in patient prostate tissue. Notable tests on the market
currently are the Genomic Prostate Score (Oncotype DX® GPS), quantification of DNA
methylation (ConfirmMDx®), the Cell Cycle Progression Score (Prolaris®), and the
Genomic Classifier Score (GenomeDX Decipher®).
The former two (Oncotype DX GPSa and ConfirmMDx), are performed on prostate
tissue from a prostate biopsy, while the latter two (Prolaris and Decipher) are
performed on tissue from the radical prostatectomy specimens.

Genomic Prostate Score (Oncotype DX® GPS)
The Oncotype DX Genomic Prostate Score Assay (GPS) is a multi-gene panel
designed to be performed on small volumes of formalin-fixed paraffin-embedded
(FFPE) prostate tissue samples taken at prostate needle biopsy. The initial study was
reported by Klein et al. (86). Gene expression was quantified in a set of
contemporary prostatectomy and biopsy specimens as a development cohort. Of
the 732 candidate genes identified, 12 genes that represented a spectrum of
biological pathways involved in PCa were found to correlate well with stage and
grade of PCa at on final pathology at RP. These were combined with 5 reference
genes to form a 17 gene panel. The GPS is a score from 0 to 100, with a higher score
indicating higher relative risk. The test was then validated in a low- to intermediate
risk PCa population deemed eligible for active surveillance but who had radical
prostatectomy, to determine whether it could accurately predict adverse pathology
at RP. In the validation component of the study, 31% of the patients were deemed to
have adverse pathological features. These were Gleason score of ≥4+3 or
pathological extraprostatic disease. Significant positive correlation was found
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between GPS and adverse pathology. For every 20 unit increase in GPS, the RR for
extraprosatic disease increased by 1.9 and the RR for high grade disease increased by
2.3.
These findings were further validated in an external cohort of 402 cases (87). In a
secondary analysis of those two cohorts, Brand et al. showed that NCCN very low risk
men had an 80% likelihood of favourable pathology, which comprised 11% of the
combined cohort (87). When using the GPS in combination with the NCCN risk group,
the proportion of men with an 80% likelihood of favourable pathology was increased
to 23%. When GPS was utilised in conjunction with the CAPRA score, the proportion
increased to 31%. This demonstrates the risk stratification potential of the test, and
potential use in decision-making in an active surveillance setting. Prospective
validation of these findings would lend strength to the evidence.
In a study to determine the clinical usefulness of the Oncotype DX, Badani et al.
interviewed urologists on their hypothetical treatment recommendations using a
cohort of 157 men who had undergone both the test and subsequent radical
prostatectomy (88). They found that there was discordance between the NCCN risk
group and the Oncotype DX risk score in 37% of men. The test led to a 24% higher
relative rate of recommending active surveillance (absolute difference of 41% vs
51%) and the clinicians were of the opinion that the test was clinically useful in 79%
of patients. Although the authors proved that the test might have changed the
clinical recommendation, there was no evidence presented that the altered
recommendations were any better.

DNA hypermethylation (ConfirmMDx®)
Standard TRUS biopsy of the prostate is randomly directed, and as such can miss
foci of prostate cancer (89). However, there are epigenetic changes that can be
present in adjacent benign cells. Epigenetic changes are alterations to the DNA that
affect gene expression but are reversible and do not affect the primary DNA
sequence. DNA methylation is one such change. Methylation of certain dinucleotides
can silence expression of tumour promoters.
The ConfirmMDx EpiScore is calculated from the analysis of the DNA methylation
status of GSTP1, APC, and RASSF1 in benign prostate biopsy tissue (90). The purpose
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of the score is to estimate the risk of a subsequent prostate biopsy being positive.
The score has been designed to have a strong negative predictive value to reduce
the number of unnecessary repeat biopsies being performed for men with continued
high suspicion of prostate cancer after an initial negative biopsy. Absent DNA
methylation of all three of the genes has a negative predictive value for high-grade
(Gleason ≥7) PCa of 96%.
Van Neste et al. developed a risk score that incorporated the EpiScore along with
other clinical parameters such as PSA, age, DRE findings, and pathological findings.
For predicting men with Gleason ≥7 on repeat biopsy, this score achieved an AUC of
0.762, compared to an AUC of 0.742 for the EpiScore alone. The EpiScore has been
validated in several external cohorts (91,92). The conclusion is that this test could
reduce the number of unnecessary biopsies by up to two thirds without missing a
significant number of significant cancers.

Cell Cycle Progression Score (Prolaris®)
The Cell Cycle Progression (CCP) score is a 46 gene panel comprised of 31 genes
responsible for cell cycle progression, in addition to 15 housekeeper genes that are
included for control and standardization. It is available commercially as the Prolaris
test from Myriad Genetics, Salt Lake City, Utah.
The test was first reported by Cuzik et al. in 2011 (93). The genes were identified in
prostate cancer tissue, and were chosen based on their individual concordance with
overall increased expression of known cell cycle promoting genes. The aim was to
measure the proliferative activity of a tumour in preference to other characteristics,
such as invasive potential, etc. The predefined score was then tested on a cohort of
men who had undergone radical prostatectomy and one who had had PCa diagnosed
incidentally on TURP, to determine the accuracy for predicting final outcome. The
CCP score was highly correlated to the risk of biochemical progression after RP (HR
1.89 for each 1 unit change in CCP score, p <0.001), and also highly correlated to risk
of PCa-specific death after incidental diagnosis following TURP (HR 2.92, p <0.001).
CCP score has been externally validated in two RP cohorts, where it again was
predictive of biochemical recurrence and cancer specific death, increasing the
concordance index from 0.71 for a clinical model (CAPRA-S) to 0.77 for a model
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combining clinical factors with the CCP (94). While a non-randomised study has
shown that CCP might alter the recommendations that a physician might make to a
patient (95), such studies do not really reflect the performance of the test, and
importantly do not demonstrate improved outcomes as a result of the altered
recommendations.
These studies have shown that the CCP score might be a good predictor of disease
outcome after treatment for prostate cancer. How this would affect clinical decisionmaking should be directed by future studies.

Genomic Classifier Score (GenomeDX Decipher®)
A test that is similar to the CCP score is the Genomic Classifier Score, available
commercially as the Decifer test from GenomeDX Biosciences, Vancouver, Canada.
An RNA microarray is performed on FFPE prostate tissue taken from an area of the
highest Gleason score in the RP specimen.
The score was first reported by Erho et al. in 2013 (96). A cohort of 639 men who
underwent RP was used for development, 213 of whom developed early metastatic
disease recurrence. Using computer learning algorithms processing data on 1.4
million markers from 545 individual tumours, the investigators identified 22 markers
that best predicted early metastasis after RP. In validation, the test did indeed
correlate well with diagnosis of early metastatic disease, with an AUC of 0.75 (0.670.83). In addition, higher score correlated with reduced time to PCa-specific death
and reduced overall survival within Gleason grade groups.
An external validation of the Decipher genomic classifier test was performed by
Karnes et al. in a cohort with more low risk men and a lower incidence of disease
recurrence (96). They found that the test increased the predictive power of a clinical
model and achieved an AUC of 0.79 (0.68-0.87) for predicting metastatic disease at 5
years.
In another validation of the test, Cooperberg et al. retrospectively studied a random
sample of 185 men from larger cohort treated with RP who were all at a high risk of
recurrence (97). GCS was strongly predictive of cancer specific mortality. 24% of the
men had a GC score of >0.6, 64% of whom died of PCa. Conversely, men with scores
lower than 0.6 had a 7% 10 year CSM. The GC score performed better at predicting
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outcome when combined with the post-surgical Cancer of the Prostate Risk
Assessment (CAPRA-S) Score. The authors conclude that Genomic Classifier Score
could be useful in selecting men for early secondary therapies or clinical trials.

Imaging
Potential tools for improved screening and risk stratification are not limited to
biomarkers. Recent improvements in imaging have recently made these modalities
viable options to fulfil these roles, with some advantages and disadvantages relative
to biomarkers.

Multiparametric Magnetic Resonance Imaging
Despite magnetic resonance imaging being available since the early 1980’s, the
utility of prostate MRI has until recently been limited. Initial investigations for
assessing prostate cancer showed MRI to have poor sensitivity and specificity for
distinguishing prostate cancer from benign disease (REF).
Recent improvements in technology as well as the combination of different imaging
techniques, namely diffusion weighted imaging, dynamic contrast enhancement, and
MRI spectroscopy, have dramatically improved the test characteristics of MRI.
ultiparametric magnetic resonance imaging (mpMRI) is now finding its place in
clinical practice. The Prostate Imaging Reporting and Data System version II (PI-RADS
II) is the standard reporting scheme for prostate mpMRI, which defines anatomical
regions of the prostate and classifies lesions on likelihood that they are malignant
(98). This system has somewhat reduced the inter-observer variation in prostate MRI
(99).
The main use for mpMRI of the prostate has been its use in conjunction with MRIguided biopsy. While various studies have used in-bore biopsy in the MRI suite or
“cognitive” guidance of regular TRUS biopsy, the majority of contemporary
publications report on MRI-ultrasound fusion technology which allows MRI images
from a recent MRI to be fused with real-time ultrasound images during TRUS biopsy
(100). Some have investigated the use of mpMRI and subsequent MRI-targeted
biopsy in biopsy naïve men with suspicion of PCa (101,102). mpMRI was found to
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improve overall cancer detection to a small extent, to increase the detection of
clinically significant PCa, and to reduce the diagnosis of clinically insignificant
cancers. This presumably makes the TRUS biopsy more representative of the true
pathological picture. However, the PPV and NPV of MRI-US fusion biopsy in the
biopsy setting is still relatively modest. So, because of the low NPV, template
biopsies are recommended in addition to targeted ones, and even in the case of a
negative mpMRI, a biopsy still needs to be done to avoid missing a clinically
significant cancer. Furthermore, because of the low PPV, many men with suspicious
lesions on mpMRI will turn out to have negative biopsies (101). mpMRI can improve
positive biopsy rates in the repeat biopsy setting and improve risk stratification for
men with apparent low risk PCa (103). However, for these indications too, the MRI
does not replace either a PSA measurement or the TRUS biopsy. In fact, without the
use of a concurrent MRI-guided biopsy, the utility of mpMRI of the prostate is
limited.
While mpMRI is has been widely incorporated into prostate cancer management
and is likely to become more widely practiced, it falls far short of being a perfect
assessment tool.

Positron Emission Tomography
Another imaging modality that has been used to evaluate men with prostate cancer
is PET scanning. Traditional FDG-PET had limited usefulness in prostate cancer due to
the relatively low metabolic rate of PCa cells compared to other cancers.
Improvements in PET scanners as well as newer technologies, such as choline, N-[N[(S)-1,3-dicar- boxypropyl]carbamoyl]-4-(18)Ffluorobenzyl-L-cysteine (18F-DCFBC),
hyperpolarised C13, and gallium-PSMA radiotracers, have improved the utility of PET
scanning (104). 68Ga-PSMA has shown highest promise in identifying otherwise
occult nodal and distant metastatic disease in men with high risk prostate cancer.
There is also some evidence that 68Ga-PSMA PET-MRI can improve disease
localisation within the prostate compared to mpMRI alone (105). While these
scanning technologies add clinical utility in a small proportion of men, PET would
also not reduce the burden of investigation.

21
A comprehensive review of imaging for PCa is beyond the scope of this literature
review.

Summary
PSA is the prototypical biomarker for prostate cancer that was brought into clinical
use in 1986. It is used for screening, risk stratification, monitoring of disease
progress, and response to treatment. However its accuracy in all of these contexts is
limited because of individual variation, potential underproduction by malignant
tissue, PSA production by normal and inflamed prostate tissue, and various other
factors.
Blood

Biomarker

Basis

Role

Comment

PSA

Serum protein

Scr, RS, DM, TR

Derivatives: PSAd,
PSA-dt, %fPSA

phi

p2PSA, tPSA, fPSA

Scr, RS

Uses p2PSA, tPSA,
fPSA

4k score

tPSA, fPSA, iPSA, hK2

Scr, RS

Uses tPSA, fPSA,
intact PSA, and hK2.

CTCs

Urine

Flow cytometry

RS and TR (in

Not useful in

metastatic disease)

localised PCa.

PCA3

Non-coding RNA

Scr, RS

Both require DRE

TMPRSS2:ERG

Non-coding RNA

Scr, RS

before urine
sample.

ExoDx

Exosomal proteins

Scr

No DRE required
Predicts GS≥7

Prostarix

Protein metabolites

Scr

Tissue – Biopsy

Oncotype DX

17 genes, multiple

Predicts aggressive

Tested on FFPE

specimen

GPS

pathways

PCa in low risk

tissue of highest
Gleason.

ConfirmMDx

Tissue – RP specimen

Prolaris

Hypermethylation of

Predicts Positive

Tested in benign

3 genes

repeat biopsy

FFPE tissue.

46 genes, cell cycle

Prognosis after RP

Both could be used

progression
Decipher

22 genes, predict

to select men for
Prognosis after RP

early mets

adjuvant or
investigational
therapy.

Scr = Screening; RS = Risk Stratification; DM = Disease Monitoring; TR = Treatment Response
Table 1: Biomarkers for Prostate Cancer

22

From the time of its introduction, PSA remained the only useful biomarker for PCa
until the advent of PCA3 almost 20 years later. PCA3 and a host of other non-invasive
biomarkers that were introduced subsequently have not been able to replace PSA,
but only to potentially augment its clinical role. Most have been evaluated in the
context of selecting men with raised PSA for prostate biopsy, in risk stratifying men
prior to treatment, and in predicting response following definitive treatment. Only
marginal improvements have been shown for all of these functions.
Like most cancers, histological diagnosis remains the definitive diagnosis of PCa.
While genomics performed on the biopsy specimen can improve on prognostication
of the disease, little more is gained over the standard Gleason histological grading.
Newer imaging modalities, including mpMRI and PET scanning, occupy the same
clinical space as many of these described biomarkers, but these too have not
replaced PSA and prostate biopsy.
This review has highlighted the need for newer and better biomarkers for prostate
cancer to reduce overinvestigation, overdiagnosis, and overtreatment of prostate
cancer, while reducing deaths from the disease.

Extracellular Vesicles and Prostate Cancer
Extracellular vesicles (EVs) are membrane-bound cell fragments that range in size
from 30-100 nm, and are derived from various cell populations (106). They are found
in almost all biological fluids (107). EV membranes can be derived from the outer cell
membrane of their cell of origin, and because of this often share the same surface
proteins and other antigens. EV’s contain proteins, RNA, DNA, and other cytoplasmic
substances common to the cell of origin.

History
Circulating cell fragments were first described by Wolf in 1967 (108). He identified
these subcellular particles by ultracentrifugation of platelet poor plasma and
electron microscopy, and correctly recognised their platelet origin. The term he
coined at the time was “platelet dust”. He found that these particles were lipid-rich,
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and that they were responsible for the thrombogenic properties of plasma that had
previously contained activated platelets.
The role of these particles in thrombosis became more clearly elucidated over time,
but it was some time before it was realised that other cells also released similar
microvesicles.
The first description of extracellular vesicles being released from neoplastic cells
was from Trams et al. in 1981 (109). Electron microscopy was used to examine
conditioned culture medium from various mouse, rat, and human cells – among
which were neuroblastomas, gliomas, astrocytomas, and melanomas.

Classification and Origins of EVs
Extracellular vesicles are nano sized bodies that consist of cytoplasm and a
surrounding cell membrane derived from the cell of origin. The multidisciplinary
nature of this field of research, as well as the many poorly understood aspects of
microvesicle physiology, has led to a diverse and often conflicting nomenclature
Some names give clues to the cell of origin (e.g. prostasome, oncosome), while
others refer to their size or functional origin (e.g. exosome, ectosome) (110).
Based on a recent consensus conference, the international society for extracellular
vesicles has recommended that the term “extracellular vesicle” be used for all such
membrane-bound subcellular structures. Allowance, however, is made for individual
scientists to use their discretion in choosing their preferred term, as long as their
reports contain accurate descriptions of the methods used to isolate and study the
particles concerned (110).
Subdivision of EVs is usually then based on size, into “exosomes”, “microparticles”
(interchangeable with “ectosomes”), and “apoptotic bodies”, which correlates to
some degree with the origin of the particles (111). The usual upper limit of size for
EV’s is 1 µm, since normal platelets can be as small as 1-3 µm (112). Exosomes are
extracellular vesicles that are produced via the endocytic pathway (111). They are
formed inside cells as intraluminal vesicles (ILV) within multivesicular bodies (MVB).
The ILVs within the MVBs are derived from the outer membrane of the cell, but
endocytosed into the cell. Enrichment of the ILVs with various lipids and proteins can
occur. Exocytosis of the MVB releases the ILVs into the extracellular environment,
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which are then referred to as “exosomes” (113). Exosomes are typically 30-100 nm in
size, although the upper limit can be considerably higher than that. Exosomes have a
classically cup-shaped appearance under transmission electron microscopy, although
this may be an artefact related to sample preparation (110). Microparticles (MPs)
are extracellular vesicles that arise directly from budding of the outer cell membrane
into the extracellular environment (113). They are typically defined as being
between 100-1000 nm in diameter. Microparticles are referred to interchangeably as
ectosomes or microvesicles (114). Apoptotic bodies are membrane-bound cell
fragments, generally larger than 750 nm that are released during apoptosis. Apart
from the size discrepancy between exosomes and MPs, where there is most likely an
overlap, there is no reliable way to distinguish one from the other when found freely
(111). Among healthy people, approximately 70-90% of EVs in the blood are derived
from platelets, with the remainder being produced by leukocytes, endothelial cells,
and red blood cells (115). There is a small proportion of EVs present in the circulation
that is derived from cells outside the circulatory system, which can vary substantially
in various disease states.

Qualitative and Quantitative Measurement
There is no standard qualitative or quantitative technique for microparticle analysis,
despite the increasing volume of research in the field (115). In the original paper by
Wolf, EVs were observed in ultracentrifuged platelet-poor plasma using electron
microscopy (108). Since then, many other techniques for identifying, counting, and
characterising exosomes and MPs have been described.
Analysis consists of determining concentration, measuring size, and determining
qualitative aspects such as surface antigens and cytoplasmic contents such as RNA,
DNA, and protein constituents.
Flow cytometry is perhaps the most commonly used technique for quantifying
microparticles and it has been suggested that it should be the reference method of
choice (116). When performing flow cytometry, techniques for discriminating
microparticle populations from one another include: staining with either fluorescent
dyes or with antibodies labelled with fluorescent molecules, or by their various lightscattering properties (112). These properties include their degree of forward scatter
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and side scatter (Figure 1), which correlate with their size and internal complexity,
respectively. The flow cytometer can be calibrated with artificial microspheres of
known size. These can be composed of latex or silica (117). Fluorophore-labelled
monoclonal antibodies specific to a relevant cell surface antigen can then be used to
identify EVs of interest. Isotype controls that are derived from the same species
should be used to control for non-specific antibody binding (118). An appropriate
isotype control is an antibody of the same class as the test antibody and derived
from the same animal, but without a specific target. The marker used for detection
of MPs using flow cytometry in many of the earlier studies was Annexin V, although
now there are Annexin V-negative MPs that have been described (119). Targeting a
surface antigen that is more specific to the EV population of interest can be more
useful when analysing complex fluids. With the use of flow cytometry, there is some
evidence that some large protein complexes can be confused with MPs due to
similar properties such as size, light scatter, and sedimentation (120). Flow
cytometry is the quickest and easiest method of quantifying EVs and determining the
cell of origin (121). The disadvantage of flow cytometry is the inability to analyse the
composition of the vesicles.
To analyse the composition or other properties of EVs, a process of isolation needs
to be performed. As with nomenclature, there is no standardised method of isolating
EVs for analysis (119). An international survey of researchers with respect to
methods used for EV isolation and characterisation revealed that ultracentrifugation
was most commonly used (122). This technique isolates EV populations in terms of
size by serial centrifugations at progressively higher spin rates and longer time.
However, slight differences in centrifugation protocol risk selective depletion of MP
population (119). To remove platelets from a suspension, an 800 nm filter is
required, and this should ideally be gravity-driven rather than forced, to prevent
platelet fragmentation. Very often, ultracentrifugation is used as the initial step in a
multi-step process. Further isolation can then be performed using techniques such as
microfiltration, magnetic bead sorting or fluorescence activated cell sorting (FACS)
(123). Once isolated, EVs or their constituents can be analysed using techniques such
as transmission EM, atomic force microscopy, Western blotting, or PCR (124).
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Structure and Function
The production of both exosomes and MPs are cellular functions that are highly
evolutionarily preserved, occurring in all eukaryotic cells, with very similar processes
present in prokaryotes (125).
MPs seem to be produced via an active process of budding from the outer plasma
membrane. Phospholipid composition differs between the inner and outer leaflets of
the cell membrane. Phosphatidylserine and phosphatidylethanolamine are
maintained at higher concentration on the inner leaflet, and are both actively
transported there by an enzyme called “flippase” (126). It has been suggested that a
“floppase” enzyme can mediate ATP dependent transport of these molecules to the
outer leaflet of the cell membrane. Flippase activity is inhibited by a concurrent
influx of intracellular calcium as would occur during cell activation. The resultant
membrane asymmetry seems to be a common feature activated of apoptotic cells
releasing MPs. “Scramblase” is another enzyme that plays a role in MP release in
platelets. It allows the membrane polarity to be neutralised by allowing substances
to follow concentration gradients.
Exosomes and MPs most likely have differing functions based on their membrane
structure and protein content. Exosomes have membranes that are lipid-enriched
and have higher concentrations of signalling proteins. MPs on the other hand are
enriched with proteins associated with gene expression and translation, as well as
various enzymes.
The multiple physiological roles played by MPs are now emerging. They seem to
serve various functions related to cell homeostasis, such as regulating the surface
area and composition of the plasma membrane – part of a process called membrane
trafficking (113). MP generation could also be an important function in cytoskeleton
remodelling (126) and management of cellular waste products (107).
Many exosomes and MPs have effects external to their cells of origin. From the
time of their first discovery, it was known that MPs were released by platelets during
activation during the course of normal coagulation and fibrinolysis (112). It
subsequently appeared that these platelet MPs were most likely also key mediators
of inflammation and immunity (116).
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Intercellular communication is effected by various signalling molecules, as well as a
variety of other molecules, including RNA, proteins, and lipids (127). These molecules
act either by direct stimulation of external cellular receptors, or via delivery of a
specific cargo into a cell. There is evidence that some MPs can transfer surface
proteins or RNA horizontally between cells (127). This transfer occurs in several
different ways. It can happen via direct fusion of the EV to the plasma membrane,
with release of the constituents into the cytoplasm. It can also occur via
phagocytosis or micropinocytosis. Subsequent fusion of the vesicles with the cells
can then occur within the cells endocompartments. Clarithrin-mediated endocytosis
is a process that allows an EV to be transported directly, and intact, into the
cytoplasm (113). There is also increasing awareness that substances that were
previously thought of as free constituents of the plasma, are actually contained
within microparticles (116).
Microparticles derived from endothelial cells, platelets, and sometimes leukocytes
have been found to be increased in various disease states, such as coronary artery
disease, deep venous thrombosis, pulmonary embolism, sickle cell disease, chronic
renal failure, and others (123). Activation of various cell types, induction of
apoptosis, and promotion of cytokine secretion have all been reported in response
to certain MPs (123).
There is much literature examining potential functions of exosomes and MPs. Apart
from their previously well-established role in thrombosis, there is evidence that
some EVs have immune suppressing abilities, can present antigens to immune cells,
transfer signalling proteins, promote inflammation, transfer genetic information, and
promote tumour growth (107). Viral particles and prions have been found within
EVs, suggesting that they might be involved in pathophysiological processes or
disease transmission.

Microparticles in Cancer
The first report of tumour-derived MPs was by Trams et al. in 1981 (109). Other
investigators in the early 1980s reported finding similar microvesicles in other
malignant cell lines (114). Interestingly, Trams et al. observed a bimodal population
of EVs, with one set at approximately 50 nm and another population at 500-1000 nm

28
in diameter. This might correspond to populations of exosomes and MPs,
respectively. However, early investigators only reported observing vesicles arising
from the outer plasma membrane. It was not until 2001 that Wolfers et al. showed
that tumour-derived EVs were also produced in MVBs and released as exosomes
(128).
Overall circulating EV concentrations have been found by some to be significantly
higher in cancer patients, compared to healthy controls (129). A large part of this
increase may be due to higher concentrations of platelet MPs, but that increase may
also be due to MPs originating from tumour cells themselves. Microparticle tissue
factor activity is increased in several different cancers, including prostate cancer
(130). Whether this increased tissue factor activity is from platelet-derived
microparticles or those directly from cancer cells is not clear. Increased MP tissue
factor activity plays a role in the link between malignancy and increased risk of
thrombosis. Circulating tumour-derived MPs carry tumour-specific antigens on their
surface, such as HER-2, CEA, and EGFRvIII [19, 157, 159].
It was initially thought that EV release from malignant cells was an aberrant process
taking place in dysfunctional cells, but there is abundant evidence that this process
serves various physiological functions. Tumour-derived MPs have been shown to not
only carry protein and genetic cargo, but to be actively enriched in these substances
(131). This might be part of a waste-clearing process, by carrying away excess cell
membrane and cytosolic products, or as a way to influence the micro- or macroenvironment.
It has been postulated that MP generation by tumours could play roles in defensive
or offensive responses to the host immune response (132). Valenti et al. showed
that melanoma and colorectal carcinoma MPs could inhibit the differentiation of
monocytes, or promote their development into myeloid-derived suppressor cells
(133). They therefore have an immunosuppressive effect that would serve to
promote tumour survival. Surface proteins shed by MP release could also divert
drugs as well as antibody and cellular immune responses. They could also be used to
actively export substances such as cytokines or intracellular drug (132). Tumourderived MPs may also act in a paracrine and juxtacrine fashion to transfer
chemotherapy and radiation resistance between nearby cells (134).
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There is also evidence that tumour-derived EVs have effects that could promote
oncogenesis in other cells, facilitate metastasis by promoting cell invasion, or
promote angiogenesis within the tumour microenvironment.
Keerthikumar et al. performed a proteogenomic analysis of exosomes and
endosomes derived from cancer cells (111). They found that certain proteins known
to be associated with various types of cancers, including specific mutant proteins
associated with oncogenesis or drug resistance, were enriched within exosomes and
MPs. This occurred to a greater extent in exosomes compared to MPs, although
some proteins were exclusively found in one or the other. This suggests that these
extracellular vesicles could play a role in cell proliferation or cell migration. The
enrichment of these tumour-specific proteins was also highlighted as a promising
potential source for biomarkers for these cancers. There is some evidence that these
tumour-derived EVs are capable of microRNA (miRNA) biogenesis, which is a feature
not present in EVs derived from normal cells (129). Cells incubated with cancer EVs
have also been shown to exhibit increased rates of malignant transformation,
suggesting that the transfer of miRNAs could confer a field effect that causes
surrounding benign cells to also undergo malignant transformation (129).
Janowska-Wieczorek et al. observed that platelet-derived MPs could transfer
various matrix metalloproteins (MMPs) to breast cancer cells and thereby increase in
vitro measures of invasiveness (135). Skog et al. showed that MPs derived from
glioblastoma cells contained angiogenic mRNA, miRNA, and proteins. These MPs are
taken up by endothelial cells, and the authors demonstrated a resultant increase in
angiogenesis (136).

Microparticles and the Prostate
Both seminal fluid and expressed prostatic secretions have been shown to have
high concentrations of EVs (137). Submicron vesicles were detected in the seminal
fluid by a group from Uppsala University in Sweden in the late 1970s. Using electron
microscopy, they found evidence that these vesicles were produced by the prostatic
glandular epithelial cells, where they were observed to be present within larger
vacuoles (138). The same group proposed the name “prostasome” for this new
microvesicle that was actively secreted into the glandular lumen by various
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mechanisms. Much work has subsequently been done on investigating the structure
and function of prostasomes.
The group initially used purified EVs isolated from semen to generate their own
anti-prostasome antibody (139). The primary antigen was subsequently found to be
dipeptidyl peptidase IV (DPP IV), also known as CD26 (140). Prostatic exosomes are
composed of a high proportion of cholesterol, sphingomyelin, certain enzymes, and
calcium (141,142). They have a heterogeneous size, varying from 40-500 nm, with a
mean diameter of 120-150 nm (11). Using EM, the group observed prostasome
generation occurring within MVBs in prostatic luminal cells. Their contention is that,
despite their size of up to 500 nm, these EVs are exosomes rather than MPs. There
are, however, currently no reliable markers available for distinguishing exosomes
from MPs (111).
The proposed normal functions of prostatic EVs in the ejaculate are to support
certain spermatozoal functions as well to interact with the microenvironment within
the female genital tract (141). They protect spermatozoa from acidic pH changes
(which occurs via fusion of these vesicles with the spermatozoa in low pH
conditions), delay the acrosome reaction, enhance sperm motility, transfer
enzymatic activity (such as CD26) to spermatozoa, and suppress the local female
immune response (141). Prostasomes have been shown to have the capacity to
generate ATP via the glycolytic pathway (143). This process might be important for
supporting spermatozoa within the female genital tract. Ronquist et al. has proposed
a theory that prostasomes from benign cells might play a role in malignant
transformation of prostate glandular cells via transfer of matrix metalloproteinases
(139).
Malignant prostatic epithelial cells also produce EVs. EM studies in malignant
prostate tissue have shown that PCa cells have golgi-associated storage vesicles
containing various prostasome precursors (139). These early MVBs are also present,
although to a lesser degree, in metastatic PCa cells, suggesting that even very
malignant prostate cells retain the ability to produce exosomes. The same group did
indeed identify prostasomes surrounding surgically resected vertebral PCa
metastases (144). Not only do they retain the ability to produce exosomes, but they
may produce more plasma membrane-derived MPs. The cytoskeletal regulator
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Diaphanous-related formin-3 (DIAPH3) is often lost in PCa, and this loss leads to an
amoeboid cells that shed large quantities of large EVs (145).
As with other malignancies, it seems that tumour-derived MPs from PCa cells have
functional roles that promote neoplastic transformation and malignant behaviour.
In an intriguing and very complex study, Abd Elmageed et al. isolated adipose stem
cells derived from prostate cancer patients, selectively cultured those with a
particular tropism for conditioned media of PCa cells, and then exposed these cells
to PCa-derived MPs (versus control), and injected the cells into athymic nude mice
(146). The stem cells that had been exposed to the PCMPs developed into large
aggressive tumours that showed histological and biochemical mimicry of prostate
cancer cells. This study further illuminates the role that MPs might have in
influencing their host environment, and might explain the observed clinical
correlation between disease aggressiveness and raised BMI.
Ramteke et al. demonstrated that LNCaP and PC3 prostate cancer cells grown
under hypoxic conditions (1% O2) produce exosomes that were structurally and
constitutively different to those produced under normoxic conditions (147). Not only
were they smaller, they had higher concentrations of various signalling molecules
such as TGF-b2, TNF1a, IL6, b-catenin, and others. They also had higher levels of
tetraspanins (CD63 and CD81), heat shock proteins (HSP90 and HSP70), and Annexin
II. Naïve cells grown in the presence of these exosomes then showed greater motility
and invasiveness. These findings could suggest that hypoxic prostate cancer tissue in
vivo promotes tumour aggression via MP release.

Role as a Prostate Cancer Biomarker
Platelet EV levels have been investigated in PCa. Men with advanced PCa have been
found to have increased levels of platelet MPs, and these levels correlate with
disease-specific and overall survival (148). Another group has shown increased levels
of MP-derived tissue factor in men with localised PCa (149). In these men, the values
returned to normal within one week after RP.
Tumour-derived MPs carry tumour-specific cell surface antigens, proteins and
genomic cargo (150). These can be used to identify the origin of the MP populations
and can also indicate specific phenotypic properties of the tumour. These features
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have potential as biomarkers for diagnosis, staging, risk stratification, or for
personalised treatment selection.
Recently, several investigators have analysed prostate-derived EVs in plasma or
urine in search of new biomarkers (137). These have varied from known proteins
(such as PTEN and survivin) to miRNAs and N-linked glycans.
An investigational proteomics study by Hosseini-Beheshti et al. identified over 220
proteins in a panel of PCa cell lines, some of which were previously thought to be
only present in cell nuclei (151). Khan et al. found that exosomal survivin levels were
higher in men with PCa compared to men with BPH and healthy volunteers –
showing promise for potential biomarker application (152).
Mizutani et al. studied PCMPs derived from conditioned media from LNCaP and PC3
cells (153). The media was ultracentrifuged, and the resuspended pellets then
incubated with magnetic beads coated with anti-CD9 and anti-PSMA antibodies, with
subsequent Western blotting. Using this technique, isolated MP populations from
both CD9 and PSMA groups had identifiable androgen receptors (AR) present. The
group then used the same technique to isolate prostate MPs from 5 men with PCa
and 2 controls. All 5 had high grade PCa, but PSMA MPs were only different to
controls in 3 of the men, all of whom had high volume metastatic or castrateresistant disease. This study showed that PCMPs carry AR, and also that PSMA is a
useful marker of these MPs. The method of using magnetic beads might limit the
detection of lower quantities.
Prostate microparticles have also been identified in the urine. Duijvesz et al. used a
time-resolved fluorescence immunoassay (TR-FIA) to identify MPs in ultracentrifuged
urine of men with PCa and in controls (154). Samples were incubated in biotinylated
CD9 and CD63 antibodies, then transferred to streptavidin-coated plates, after which
Europium-labelled CD9 and CD63 antibodies were used for detection. They found
significantly higher levels of prostate MPs in the urine of men with PCa compared to
men without PCa, women, and men post RP. The team also investigated the
influence of DRE prior to specimen collection. Interestingly, they also found that a
DRE prior to specimen collection significantly increased the concentration of
prostate MPs in all men. The CD9 and CD63 assays were separate, and they did not
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test for dual positives. ROCs generated for each of the assays showed AUCs of 0.59
and 0.68 for CD9 and CD63, respectively, compared to an AUC of 0.61 for serum PSA.
Mitchell et al. analysed urinary EVs in PCa patients using ultracentrifugation and
immune-blotting (155). They found that men with PCa had a 1.2x higher urinary
concentration of prostate-derived EVs, and this dropped rapidly with the
commencement of ADT. This is an early exploration of the use of PCMPs for disease
monitoring. Another interesting finding from this paper was the finding that urinary
EVs were stable in urine for longer than 18 hours at 37°C and that they were
resistant to both osmotic and proteolytic damage.
There has been little work done on simple enumeration of prostate-derived MPs
using flow cytometry. Our laboratory at Lawson Health Research Institute (LHRI) has
recently published our experience of using nano-scale flow cytometry in conjunction
with fluorophore-labelled antibodies to prostatic surface antigens (156). Using a
monoclonal antibody to prostate-specific membrane antigen clone 3E7 (PSMA-3E7)
conjugated to phycoerythrin (PE), our team tested plasma samples from men with
localised and metastatic prostate cancer, men with BPH, men after radical
prostatectomy, and male and female healthy volunteers. While the quantities of
PSMA positive MPs were significantly higher with Gleason ≥8 tumours, they did not
reliably distinguish between Gleason 6, Gleason 7, and BPH. The finding that there
was a degree of positivity among men post RP as well as male and female healthy
volunteers led our team to conclude that there was a degree of non-specificity of the
PSMA clone used. Unpublished data from our laboratory shows greater specificity
using multiple antibodies, which will be discussed below.

Cell surface antigens
Prostate cancer cells are known to express many different surface antigens,
including CD9 and CD63 (153). Of interest to the study are three different cell surface
antigens on benign and malignant prostate cells, namely PSMA, STEAP1, and
polysialic acid. Also notable to this study are cell surface antigens present on
microparticles derived from platelets and endothelial cells. CD41a and CD31 are
expressed on MPs derived from platelets and endothelial cells respectively.(157).
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A recent study on proteomic analysis of prostatic extracellular vesicles identified
over 300 different proteins (158). They found high concentrations of PSAantichymotrypsin complex, as well as many others. There are several limitations to
this and similar studies. The proteomic assay used, although able to detect over
1,200 different proteins, is not able to detect proteins specific to the prostate, other
than PSA. Differing technologies and difficulties purifying the extracellular vesicles
also make for large inter-study variations.
It has been shown that tumour-derived MPs carry the cell surface proteins of their
parent cells (159), which rationalises the approach of using known cell surface
antigens of a particular cell type to identify MPs from those cells.

Prostate-Specific Membrane Antigen (PSMA)
Prostate-specific membrane antigen (PSMA) is the protein product of the gene
officially known as FOLH1, which is a glutamate carboxypeptidase. It is a type II
transmembrane glycoprotein that has folate hydrolase activity, and is produced
mainly by prostatic epithelial cells (160). PSMA is also detectable in cells of the
duodenal mucosa, some proximal renal tubules, and neuroendocrine cells of colonic
crypts. Immunohistochemical (IHC) studies have shown that benign and malignant
prostate epithelial cells strongly express PSMA, and this expression is maintained in
metastatic cells in the majority of cases (161).
An initial IHC study by Sweat et al. showed PSMA immunoreactivity of 46.2% ±
27.5% for benign tissue versus 79.3% ± 18.5% for prostate cancer tissue (161).
Staining was similarly high in 98% of metastatic lymph nodes examined. Although
not commonly expressed by other tumour cells, PSMA expression has been
demonstrated in neovascular endothelium of a wide variety of other neoplasms,
such as renal cell, urothelial, and colonic carcinoma (162). Multiple authors have
reported that increased tissue expression of PSMA in PCa measured with
immunohistochemistry correlates with tumour grade, PSA, and biochemical
recurrence (163–165).
Levels of free PSMA in the blood have been tested as a biomarker for PCa. In 1996,
Murphy et al. examined multiple cohorts of patients at initial biopsy, repeat biopsy,
at radical prostatectomy, and at diagnosis of metastatic disease (166). Serum PSMA
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level was found not to be predictive of positive biopsy, with an AUC of 0.53, but it
did correlate with disease progression among men with metastatic disease.
Interestingly, PSMA levels were higher in men up to 4 years after prostatectomy
compared to their pre-surgery levels. This study showed that free serum PSMA was
not a feasible biomarker.
PSMA has shown utility for several clinical applications. The first widespread
application was in nuclear scintigraphic imaging. Indium-labelled capromab
pendetide anti-PSMA antibody was approved by the FDA for imaging purposes –
available commercially as “Prostascint”. Unfortunately the imaging used lacked
sensitivity or specificity most likely due to the fact that the antibody targeted the
intracellular epitope of PSMA (167). Although still commercially available, Prostascint
is not recommended by any major guideline due to its limited usefulness.
More recently, second generation antibodies to the external domain of the protein
have produced improved results, also notably in the imaging sphere. 68Galliumlabelled PSMA antibodies used in PET scanning have showed substantially better
performance over older PET tracers, and usage is becoming widespread in many
places (168).

Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1)
Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is a membranebound enzyme of the metalloreductase family (169). It is more correctly referred to
as “metalloreductase STEAP1”. It was first described by Hubert et al. in 1999 (170).
Initially, because of its configuration and location at intercellular junctions, it was
thought to be a channel or transport protein. STEAP1 and its relatives (STEAP 2,3,
and 4) have subsequently been shown to be metalloreductases, responsible for
reducing iron from the ferric (Fe3+) to the ferrous (Fe2+) state, as well as reducing
copper from the cupric (Cu2+) to the cuprous (Cu1+) state (169). This function is most
likely necessary for transportation of these metals into the glandular lumen. Both
iron and copper are present in the normal ejaculate, and are most likely
physiologically important (171,172).
STEAP1 can be demonstrated on cell surfaces by immunohistochemistry. It has
been shown to be overexpressed in prostate cancer cells compared to benign
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prostate cells. The degree of STEAP1 overexpression has also been shown to
correlate positively with Gleason score and with biochemical recurrence following
treatment (173,174). Ihlaseh-Catalano et al. studied STEAP1 and STEAP2 RNA
transcript levels using RT-PCR in normal, malignant, and hyperplastic prostate tissue
(173). A non-significantly higher level of STEAP1 transcripts was found in higher
Gleason tumours and also in patients who subsequently presented with recurrent
disease. Multivariate analysis showed that STEAP1 expression (but not STEAP2) was
an independent predictor of worse prognosis in PCa.
STEAP1 has also been found to be overexpressed in 10 other cancers, and
overexpression specifically correlates with worse prognosis in colorectal cancer,
acute myeloid leukaemia, multiple myeloma, and diffuse large B cell lymphoma
(175).

Polysialic Acid
Polysialiation is a unique post-translational modification that occurs on neural cell
adhesion molecules (NCAMs). Polysialic acid is an unusual oligosaccharide that is
found almost exclusively on the NCAM molecule. As the name suggests, NCAMs are
(along with the cadherins) responsible for cell-cell adhesion. Although particularly
abundant in neural tissue, but they are also prevalent on many different cell types
throughout the body, particularly in epithelial and endothelial membranes.
The adhesion properties of NCAM can be modulated by a specific process of
polysialation (176). Polysialic acid is an α2,8-polymer of the carbohydrate molecule
N-acetylneuraminic acid (177). Polysialation of NCAM results primarily in reduced
cell-cell adhesion. And this function is thought to be important in growth and
development of tissues (178). Areas of the brain that exhibit high polysialic acid
expression have high neural plasticity (179). It is particularly highly expressed in the
hippocampus, and has been shown to play a role in spatial memory (180). Two
polysialyl-transferases in the golgi apparatus, ST8SiaII and ST8SiaIV, are responsible
for polysialation (178). Inhibition of these enzymes in mice leads to fatal
maldevelopment with major defects in brain morphology.
Increased polysialation in malignant cells was first noted in 1973 by van Beek et al.
(181). Polysialic acid interferes with cell adhesion because of a physical inhibition of
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the NCAM molecule to which it is attached, as well as nearby cadherin molecules
(179). The strongly anionic charge of polysialic acid also produces repulsive forces
between cells. This process is upregulated in certain neoplastic cell types, with the
resultant reduced cell-cell adhesion facilitating metastatic behaviour. The degree of
polysialation can be dramatic, with the polysialic acid component sometimes being
more massive than that of the NCAM molecule to which it is adherent (>100 kDa).
Because of the abundance of NCAM on many cells, this could produce a complete
outer carbohydrate coating to a cell (176).
Increased polysialation has been documented to occur in non-small cell lung
cancer, Wilms’ tumour, neuroblastoma, pancreatic carcinoma, and others (182). In a
murine model of pancreatic carcinoma, experimental loss of NCAM induces
metastatic spread, mainly to lymph nodes (183).
Polysialation in PCa has to date not been described. Unpublished work from our
laboratory at LHRI has shown that polysialic acid is consistently expressed on
cultured PCa cells and is detectable by flow cytometry on MPs in conditioned media.
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Chapter 2: Study Methodology
Background
Previous work done in Dr Hon Leong’s laboratory by Karla Williams, Colleen Biggs,
Sabine Brett, Khurram Siddiqui, and others investigated prostate MPs using nanoscale flow cytometry (156,184). Their investigations focused on analysis of patient
plasmas from men with no prostate pathology, benign prostatic hyperplasia,
localised PCa, and metastatic PCa. Analysis was performed on patient plasma
samples from healthy volunteers, as well as from men with benign prostatic
hyperplasia (BPH), localised PCa, and metastatic PCa, in an effort to develop a
biomarker to accurately identify their stage. The ultimate aim was to develop a noninvasive biomarker that could accurately discern high grade localised prostate cancer
from low grade disease.
Using fluorescent-labelled antibodies targeting various cell surface antigens specific
to benign and malignant prostate cancer, populations of microparticles in the plasma
samples were isolated that were likely to be derived from prostate cells. Using two
or three antibodies, with different fluorophores of unique peak emission
wavelengths, improved the specificity of the test.
The most promising combination of markers was that of prostate-specific
membrane antigen (PSMA), six-transmembrane epithelial antigen of the prostate 1
(STEAP1), and polysialic acid. PSMA and STEAP1 are both transmembrane proteins
found on normal prostate cells. Their physiological functions involve folate
metabolism and reduction of iron and copper, respectively. Both have been found to
be overexpressed in prostate cancer. Polysialic acid is a post-translational
modification of the NCAM molecule that has been found on cell surfaces of a variety
of different tumours. Work done in our laboratory had shown that polysialic acid is
expressed strongly on PCa cells. Unpublished data from the Leong laboratory
showed that the triple test could distinguish Gleason 4+3 PCa from benign or low
grade disease with an AUC of 0.86, which is substantially better than most biomarker
tests.
It is known that digital rectal examination increases the level of serum PSA. DRE
also increases the concentration of secretory products of the prostate (such as PSA),
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as well as genetic biomarkers (such as PCA3 and TMPRSS2:ERG) in first void urine. It
is unknown what the acute effects of surgery are on these markers.

Objectives of the DRE Study
The primary objective of the study was to determine whether a digital rectal
examination in men known with prostate cancer would increase plasma PMP
concentrations.
Secondary objectives were to determine whether microparticle levels were higher
than at baseline after the surgery, and whether they returned to below the baseline
at post-operative follow-up. Another secondary objective was to determine whether
microparticles could be detected in the urine of these men, and if the levels are
influenced by digital rectal examination.

Recruitment
Ethics approval was obtained from the Western University institutional research
ethics board (REB) prior to patient recruitment (REB #107043, see Appendix 2). The
study was carried out according to the Declaration of Helsinki and established Good
Clinical Practice guidelines.
All men booked for robotic radical prostatectomy at an academic referral centre in
London, Ontario, were considered candidates for recruitment. Men were identified
and approached either in the clinic when booked for surgery, or during the
preadmission process on the day of surgery. Fully informed consent was taken and a
letter of information, that included contact details for the investigators, was given
for the participants to take home.

Specimen Collection and Processing
Each patient was given a study number to de-identify the case report form (CRF)
and specimens. Data was collected on age, most recent PSA value, prostate volume,
Gleason score at biopsy, number of cores taken, number of cores positive,
percentage cores positive, and presence of atypical histological features (See
Appendix 1). Participants were asked to give a voided sample of urine within an
hour before entering the operating room. Men who were unable to produce this
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sample had urine taken via an in-out catheterisation after induction of anaesthesia.
The first urine specimen was labelled “Urine Specimen A”. After induction of
anaesthesia, as part of routine anaesthetic practice at our institution, a radial arterial
line was placed for invasive blood pressure monitoring. All intraoperative blood
specimens were drawn from the arterial line after aspiration of 10 ml to purge saline
from the line. A baseline blood sample was taken, labelled “Plasma Specimen 1”.
Then a vigorous DRE was performed for at least 2 minutes, with firm strokes from
lateral to medial on alternating sides of the prostate. At 5 minutes post-DRE, the
second blood specimen was taken, labelled “Plasma Specimen 2”. The second urine
sample, labelled “Urine Specimen B”, was taken after passage of the urethral
catheter immediately prior to starting the surgery. Once the prostate had been
completely freed from all attachments intraoperatively, the third blood sample was
taken, labelled “Plasma Specimen 3”. Participants were seen again in the urology
clinic during their routine follow-up between 3 weeks and 3 months following their
surgery. A fourth blood sample was drawn at that time, labelled “Plasma Specimen
4”.
Blood and urine samples were processed as soon as possible following surgery, or
after collection in the clinic. Each 10 ml vial of blood and 20 ml of each urine
specimens were centrifuged at 3,000 G for 15 minutes. This was to generate platelet
poor plasma and to pellet out urine sediment, respectively. Plasma was divided in
500 µl aliquots, and placed into cryopreservation vials. Each 10 ml blood sample
generated ± 10 aliquots. Urine supernatant was similarly aliquoted into 10
cryopreservation vials per sample at 1.5 ml per vial.
Initial samples were stored at -20°C, but concerns about MP stability at that
temperature led us to transfer to -80°C storage. This affected sample from the first 5
patients in the cohort. All samples collected subsequently, were flash-frozen to -80°C
immediately following centrifugation. No cryopreservation agent was used.
Thawing of specimens for the purpose of analysis was done by a rapid thaw in a
37°C bath in an attempt to minimise MP loss. At each thaw, the cryo vial was marked
in order to track the number of freeze-thaw cycles for each aliquot. Re-freezing of
samples was also done via flash freezing to -80 °C. When repeated analyses were
performed, our preference was to use samples that had previously not been thawed.
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Although there is debate in the literature about the optimal method of freezing and
thawing, ours is consistent with processes followed in many other laboratories (121).

Antibody Conjugation
The principles of antibody labelling in the context of this series of experiments are
as follows. Antibodies directed against cell surface antibodies are selected, with a
strategy of targeting multiple antigens to improve the specificity of the test. The
antibodies are labelled with fluorescent dyes that absorb light maximally at a specific
wavelength, and release light at a slightly longer wavelength with a predictable
maximal emission frequency.
Fluorophores to be used in this study were selected to have as little overlap of
emission spectra as possible, while still being compatible with the lasers equipped on
the flow cytometer in the laboratory. Commercial fluorophore-protein conjugation
kits were used to conjugate the antibodies according to their specified protocols. The
three fluorophores used were: fluorescein isothiocyanate (FITC), phycoerythrin (PE),
and Alexa Fluor 647. These molecules have emission maximums at 519 nm (green),
575 nm (orange), and 665 nm (yellow), respectively (Figure 1).
Antibody concentrations were measured before conjugation using both a
NanoDrop microvolume spectrophotometer and a Bradford spectroscopic protein
assay. Concentrations were optimised prior to conjugation and assumed to be
equivalent to the final concentration after conjugation. Determinations of the
protein concentrations after conjugation using spectroscopy were found to be
unreliable due to the absorbance of the fluorophore. This was less of a problem with
the Bradford assay generally, except for PSMA-PE, where Bradford overestimated
protein concentrations by at least one order of magnitude. This was thought to be
because PE is itself a large protein that could multiply bind to one antibody
molecule. Its maximum absorption frequency being close to that measured in the
protein assay, combined with a very high extinction coefficient, mean that it would
absorb far more light at 595 nm than ordinary protein – thus giving rise to the error..
For each antibody, their respective isotype control was conjugated at the same
concentration to the same fluorophore. When possible, conjugation of active
antibody and corresponding isotype were performed at the same time.
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Active antibodies, isotype controls, and their respective fluorophores used in the
DRE study were:


Anti-Prostate Specific Membrane Antigen (Anti-PSMA) – Clone 3E7 – Obtained
from an affiliated laboratory (Dr. Phillipp Wolf, University of Freiburg,
Germany); Isotype control: Mouse IgG2a.
o Conjugated to Phycoerythrin (PE) – Lightning-Link® R-Phycoerythrin (R-PE)
conjugation kit (Catalogue no: 703), Innova Biosciences, Cambridge, UK.



Anti-Six Transmembrane Epithelial Antigen of the Prostate (Anti-STEAP1) –
Clone J2D2 – Abcam, Cambridge, UK (Catalogue no: ab207914); Isotype: Mouse
IgG2b.
o Conjugated to Alexa Fluor 647 – Molecular Probes® Alexa Fluor® 647 antibody
labelling kit (Catalogue no: A-20186), Invitrogen, ThermoFisher Scientific,
Waltham, MA.



Anti-Polysialic Acid – Clone 735 – Absolute Antibody; Cat: Ab00240-2.0. Isotype
IgG2a.
o Conjugated to Fluorescein Isothiocyanate (FITC) – FluoReporter™ FITC Protein
Labeling Kit, ThermoFisher Scientific, Waltham, MA.

Figure 1: Fluorophores
and their emission spectra. Image demonstrates the emission spectra of the three fluorophores used in the
experiments.

Problems with Anti-STEAP1 [J2D2]
The original intention of the DRE study was to use all three antibodies to perform
triple positive tests in all samples. While this approach produced initially promising
results, quality control concern arose with the STEAP1 antibody during the study
period that could not be resolved. Antibody received from the supplier showed a
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lack of staining for MPs, whereby previous strong staining of distinct MP populations
could not be reproduced. This problem persisted despite several re-orders of the
same antibody and repeat conjugation with alternate fluorophore conjugation kits.
The same antibody clone, but in a pre-conjugated form, was procured from a
different company, and this antibody similarly did not produce the expected positive
MP populations. In communication with both suppliers, it was not clear whether
either sourced third party antibody clones.
It was therefore decided to complete the entire set of experiments using only the
PSMA and polysialic acid antibodies, analysing both single positives and dual
positives. The loss of specificity that might have resulted from such an approach
could be justified because the study analysed sequential samples from the same
patients. The non-specific component of each sample would therefore presumably
be relatively consistent from one specimen to the next. The remainder of the
discussion here deals with the analysis of dual positives of PSMA and polysialic acid,
referred to as “Prostate Microparticles” (PMPs).

Nano-scale Flow Cytometry – Calibration, Thresholds, and Laser
Settings
Flow cytometry is a process that passes a stream of fluid through a very narrow
channel and analyses the components of the fluid passing through using either
electrical impedance or laser light. The Apogee A50 nanoscale flow cytometer was
used for all experiments in this study. The device analyses the fluid stream using an
array of lasers, detecting light scatter as well as stimulated emission (Figure 2).
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Figure 2: Principles of flow cytometry. A narrow column of fluid is passed through a laser beam. Multiple light
detectors measure forward and side scatter of the laser light at the same wavelength as the primary light
source, as well as scattered light of different wavelengths caused by fluorescence.

Laser-based flow cytometers can measure individual particles in three different
ways. Forward scatter is measured by a detector located opposite the laser source,
and measures light that is minimally scattered. When analysing whole cells, the
forward (or long) angle light scatter (LALS) is a measure that correlates with the size
of the cell. A photo detector perpendicular to the laser source detects side angle
light scatter (SALS), which is a measure of the inner complexity of the cell.
Structurally simple cells, such as lymphocytes, have little side scatter, while cells with
many intracellular organelles, such as granulocytes, have more side scatter. It is not
clear whether it can be assumed that long and short angle scatter represent the
same properties when measuring subcellular particles, especially at the lower end of
the detection limit. The third characteristic of particles that can be measured is
fluorescence. Incident laser light can stimulate fluorescent molecules, which then
emit light at a different (usually a longer) wavelength. Most flow cytometers have
detectors for light at multiple wavelengths, as well as an array of different lasers to
provide excitation at appropriate frequencies. It is this function that was exploited
most in this series of experiments.
The flow cytometer that was utilised is able to report data in histographic format,
which helps to visualise, characterise, and analyse the output more easily. Initial
calibration of the machine was performed using suspensions of silica beads of
standardised size. Although silica beads have somewhat different optical properties
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to cells and EVs, the populations generated on the histograms allow for a fair
estimation of EV size. Populations generated using silica beads were marked off for
future reference on the flow template (Figure 3). The lower limit of detection for the
Apogee A50 machine is ~100 nm, below which, the output on the histogram
represents noise. This is roughly indicated by the red circle in the histogram below. A
large Region of Interest (ROI), labelled “9 MPs” in the histogram shown, counted the
total number of MPs in the sample, excluding the events smaller than 100 nm and
the noise in the lower left corner of the histogram. This ROI served as a “gate” for
MPs that performed two functions. The first was to use it to exclude all of the
smaller particles and noise from the other histograms showing fluorescence. The
second was to use the MP count as a denominator for calculating the proportion of
fluorescent or “positive” MPs in each sample.

Figure 3: LALS-SALS Histogram of sterile PBS, illustrating gates marked from silica bead calibration. Regions of
interest (ROIs) in black labelled the locations of populations of the variously sized silica beads that were
determined on previous calibrations. The red ROI labelled “noise” in the lower left portion of the histogram
indicates the location of smaller non-specific events. The green ROI labelled “MPs” was created to count the
total number of events in the size range of 100-1000 nm.

The main area of interest when analysing our samples was enumeration of
fluorescent microparticles. The software was set up with multiple histograms of LALS
vs fluorescence on the X and Y axes, respectively (Figure 4). These diagrams showed
particles of increasing size from left to right, and increasing fluorescence from
bottom to top. The histograms were also gated for MPs, as described above, to
exclude the smaller particles and noise. One histogram was created for each
fluorophore: orange for PSMA-PE and green for Polysialic acid-FITC.
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Samples analyzed without antibodies conjugated to fluorophores showed a flat
population of events with autofluorescence across the bottom of the histogram.
ROIs (red boxes 10 and 11 in Figure 4) were then drawn to exclude this nonfluorescent “noise” so that non-fluorescent samples would generate zero counts
within the gates. A third histogram showed “dual positive” events (or “PMPs”) by
essentially combining the ROIs for each of the single positives. A ROI (red box 16 in
Figure 4) drawn in this histogram counted the total number of dual positives. Figure
4 shows analysis of a single sample. The top row shows the isotype control for both
single positive and the dual positive populations. The few positive events within the
red gates likely represent non-specific binding. The bottom row of three histograms
shows MPs stained for PSMA and polysialic acid, and the dual positives.
For all samples run, records were made of the total event count per sample, the MP
count, the absolute number of positive events for PSMA and polysialic acid, and the
absolute number of dual positives. Using the MP count as the denominator, the
proportional numbers of PSMA, polysialic acid, and dual positive MPs were also
recorded.
10

11

16

10

11

16

Figure 4: Isotype controls (top row) and antibodies (bottom row) for PSMA (left), Polysialic acid (middle), and
Dual Positives (right), respectively. Active antibodies showed strong fluorescent signal outside of the baseline
noise, while the isotype controls showed only a low level of background fluorescence.

Machine settings used were as follows:


Laser thresholds: SALS at 5, LALS at 15.



No lower thresholds for any of the fluorescent detectors.



Sample size: 150 µl



Sample rate: 1.5 µl/min
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Flush cycles: 2x at 150 mbar

Optimisation of Antibody Concentrations
Optimisation of antibody to sample proportions was performed prior to running
study specimens. During the first phase of optimisation, conditioned media from PC3M-LN4 and LNCaP cell cultures was used. Optimising using these samples was
perhaps not ideal due to the wide variation in MP concentrations between different
batches of conditioned media, and recognising that the ranges of concentration
found in conditioned media might not be the same as would occur in human plasma.
For that reason, final optimisation was performed on plasma from healthy
volunteers as well as assorted plasma specimens from the DRE cohort. It was hoped
that these would represent the spectrum of MP concentrations that would be
expected.
For all optimisation experiments, the sample size was fixed at 10 µl, and
adjustments were made to the amount of antibody used. Antibody concentrations
were generally assessed with the NanoDrop spectrophotometer or Bradford protein
assay prior to conjugation. For optimisation a range of antibody masses (per 10 µl
sample) was tested. Antibodies were diluted accordingly to allow pipetted volumes
of 1-3 µl. Each optimisation was also performed with the same volume and
concentration of the corresponding fluorophore-labelled isotype control. MP counts
for each fluorophore and each sample were recorded and plotted on histograms.
MP counts tended to increase with increasing antibody, up to a plateau. Optimum
antibody mass per sample was then taken as the lowest antibody mass to give
plateau values (Figure 5).
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Figure 5: Optimisation of PSMA and polysialic acid antibodies. The same volume of plasma was incubated with
varying amounts of antibody. Positive counts increased progressively with higher mass of antibody until a
plateau was reached, indicating saturation of binding sites. Optimum antibody mass for each test was taken as
the point of inflection of the respective curve.

Optimum antibody masses for PSMA and polysialic acid were found to be 0.75 µg
and 0.8 µg, respectively. These were the amounts used for each 10 µl sample
processed throughout the study. For the complete protocols used for plasma and
urine samples, see Chapters 3 and 4, respectively.
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Chapter 3: Influence of Digital Rectal Examination on
Prostate Cancer Microparticles
Background and Rationale
Quantification of extracellular vesicles derived from the prostate is a promising
candidate as a liquid biopsy for prostate cancer. There is currently no non-invasive
test that can predict with a high degree of accuracy whether a prostate harbours
cancer, or whether or not that cancer is clinically significant. Serum prostate-specific
antigen (PSA), a secretory product of the prostate gland, is the primary biomarker
used for prostate cancer in clinical practice. It is known that a vigorous DRE (or
prostate massage) can increase the serum concentration of PSA.
It is therefore plausible that a vigorous DRE might increase the levels of prostate
cancer microparticles (PCMP) in both the blood and in the urine. Furthermore, as is
the case with PCA3, those levels might be disproportionately raised in the presence
of prostate cancer, and possibly more so with high grade prostate cancer.

Aims and Objectives
The aim of this component of the study was to investigate the effect of digital rectal
examination (DRE) on the levels of prostate cancer microparticles (PCMPs) in the
blood.
The hypothesis was that digital rectal examination (DRE) would increase the levels
of detectable plasma prostate cancer microparticles in men known to have prostate
cancer. This formed the primary objective of the study.
Secondary objectives were to determine the changes in microparticle levels
immediately after prostatectomy and at 3 to 12 weeks postoperatively, and to
determine whether DRE could improve the accuracy of microparticle analysis in
predicting histological features of prostate cancer.

Materials and Methods
Study Design: The study was prospectively planned and the protocol was approved
by the institutional research ethics board of Western University (REB #107043). The
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study was designed and carried out in accordance with local ethics regulations, as
well as with the Declaration of Helsinki.
Participants: All patients who were booked for robotic prostatectomy at an
academic referral centre (London, Ontario) were approached for participation in the
study. There were no further inclusion or exclusion criteria. Twenty-two (22)
potential participants were eligible for the study and were approached. All men
agreed to participate in the study. To detect a 50% increase in microparticle levels
after DRE with an alpha of 0.05 and a power of 80%, the required sample size was
calculated at 31. Assuming a smaller difference of 10% with the same power, the
required sample size was 83. However, since there had been no pilot study or
guidance from the literature, the degree of increase or the standard deviation of
such an increase could not be accurately estimated prior to the study. Sample
collection and analysis was therefore planned to continue in parallel, with
recruitment truncated as necessary once deemed adequate.
Sample Collection Protocol: Study ID numbers were assigned sequentially as
DRE001 to DRE022, in order to immediately de-identify specimens and case report
forms. An encrypted master list was kept behind the hospital firewall. Each
participant had four blood samples (10 ml each) taken during the study. At the study
institution, an arterial line is routinely placed for the purpose of intraoperative
invasive blood pressure monitoring. All intraoperative blood samples in this study
were taken directly from this arterial line, with 10 ml aspirated before sampling to
clear the tubing of IV fluid. The anaesthetist would assist with this procedure when
necessary. Post-operative blood samples taken in the clinics were venous blood.
After induction of anaesthesia a baseline blood sample was taken (“Plasma
Specimen 1”). A DRE was then performed for 2 minutes, with firm pressure
anteriorly, and sequential strokes from lateral to medial on alternating sides. At 5
minutes after completion of the DRE, a second 10 ml blood sample was taken
(“Plasma Specimen 2”). The third blood sample was taken close to the end of the
operation, once the prostate had been completely excised (“Plasma Specimen 3”).
At completion of the surgery, the samples were centrifuged at 3000 g for 15 minutes
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to generate platelet-depleted plasma. Each sample was aliquoted into ±10 labelled
cryo tubes, each containing 0.5 ml plasma. Samples were then stored at -80°C.
At 3 to 12 weeks postoperatively, during routine follow-up, a fourth blood sample
was drawn (“Plasma Specimen 4”). This sample was similarly centrifuged, aliquoted,
and stored at -80°C.
Specimen Testing Protocol: See Chapter 2 for more complete details on sample
handling, antibody preparation, flow cytometer settings, and antibody optimisation.
For each sample, the following were added to a centrifuge tube:
Patient plasma – 10 µl
Anti-PSMA-3E7-PE – 0.75 µg (2 µl @ 0.375 mg/ml)
Anti-polysialic-acid-FITC – 0.8 µg (2 µl @ 0.4 mg/ml)
Each sample above was prepared in duplicate, with a third sample prepared with the
corresponding isotype controls at the same volumes and concentrations.
Specimens were mixed with a vortex mixer and then spun down in a low velocity
desktop centrifuge. They were then incubated in the dark for thirty minutes. After
incubation, plasma samples were diluted with sterile phosphate-buffered saline to a
volume of 300 µl.
Samples were then analysed using an Apogee A50 nanoscale flow cytometer. Laser
thresholds were set above the level of approximately 100 nm size, based on silicon
bead calibration, to reduce noise levels. Events in the two different spectra (orange
for PSMA-PE and green for Polysialic acid-FITC) were enumerated using wide gating
to capture all potential multiple positives. Single and dual positive MP
concentrations were enumerated (as events/µl). Total event events and total events
per µl were also recorded. Using the total MP counts per specimen as a
denominator, proportional single and dual positive events were calculated and
recorded.
For each sample run, there were 7 data points generated that were considered in
the statistical analysis. These were:


Total MP count (events/µl) – all events captured by the MP ROI, which were
MPs within the threshold of ±100-1000 nm in size.
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Absolute PSMA count (events/µl) – all MPs with orange fluorescence due to PE
above the threshold.



Absolute polysialic acid count (events/µl) – all MPs with green fluorescence due
to FITC above the threshold.



Absolute dual positive count (events/µl) – all MPs with orange and green
fluorescence above the threshold.



Proportional PSMA count (%) – PSMA count as a proportion of total MPs.



Proportional polysialic acid count (%) – Polysialic acid count as a proportion of
total MPs.



Proportional dual positive count (%) – Dual positive count as a proportion of
total MPs.

CD31 and CD41a: To address questions about the origin of some of the MP
populations that arose during the study, selective samples within the cohort were
tested for CD31 and CD41a antigen reactivity. These surface antigens are present on
endothelial cell and platelet MPs, respectively.
Optimisation of these markers for analysing plasma samples with the flow
cytometer was previously done by Janice Gomes, and that protocol was used for this
experiment.
Platelet-derived MPs were labelled with anti-CD41a-FITC (clone HIP8, BD
Biosciences Cat 555466) at 25 µg/ml. The isotype control was IgG1-kappa-FITC. 1 µl
of antibody solution was added to 10 µl plasma, mixed, incubated for 30 minutes in
the dark, and then diluted 30:1 with sterile PBS. The samples were analysed with the
Apogee A50 flow cytometer using the same laser thresholds and gates as for the
PCMP experiments.
The same protocol was used to investigate for endothelium-derived EVs using antiCD31-FITC (BD Pharminogen Cat # 555445) at 50 µg/ml. The isotype control was
IgG1-kappa. 1 µl of antibody was also used in this experiment.
Patient Characteristics: 22 men were enrolled in the study between October 2016
and April 2017 (Table 2). One participant (DRE005) did not have a Plasma Specimen 1
drawn prior to DRE. One patient (DRE022) had no follow-up bloods (Specimen 4)
taken. Both participants’ data were still included in the analysis where possible.
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Mean age was 59.5 years. Preoperative data showed median PSA value and median
prostate volume on TRUS were 6.15 ng/ml and 35 ml, respectively. 6 men had ISUP
grade group 1 PCa on biopsy, 10 had grade group 2, while 8 had grade group ≥3. 19
of the men had normal prostates on DRE, while 3 had clinical T2 disease.
Characteristics of Study Participants
Participants Recruited
Age (mean)
PSA (median)

n = 22
59.5 years
6.15 ng/ml

Pre-op Data

Prostate volume on TRUS (median)
Number of cores taken at Bx (median)

12

Number of cores positive at Bx (median)

6

ISUP Grade Group on Bx (1; 2; 3; 4; 5)
Clinical T stage (T1c; T2a; T2b; T2c)

6; 10; 3; 2; 1
19; 1; 1; 1

D’Amico Risk Group (Low; Intermediate; High)

6; 13; 3

Prostate mass (median)

42.5 g

Path T stage (pT2c; pT3a)

13; 9

ISUP Grade Group (1; 2; 3; 4; 5)
ISUP Grade concordance (Down; Same; Up)
Operative Pathology

35 ml

1; 16; 4; 0; 1
4; 12 ;6

% Tumour volume (median)

15%

Calculated tumour mass (median)

5.575 g

Lymph nodes examined (median)

12

Pathological N stage

All pN0

Prostatitis

9/22

F/U

Time to follow-up bloods (3 weeks; 3 mo)
3 month PSA (<0.1; >0.1)

21; 1

Bx = Biopsy; F/U = Follow-up; ISUP = International Society of Uro-Pathologists; TRUS = Transrectal ultrasound
Table 2: Characteristics of Study Participants

Statistical Analysis: Data was entered onto a spreadsheet using Microsoft Excel
2010. Statistical analysis was performed using IBM SPSS version 23.
Variables were tested for normality using the Shapiro-Wilk test. Since almost all of
the variables were not from normal distributions, non-parametric statistical tests
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were used for the analysis. For testing the significance of differences in a variable
across all four samples, Friedman’s two-way ANOVA test was used. The MannWhitney U test was used to test for significant difference across all four samples
related to dichotomous categorical differences, namely histological grade, prostate
volume, tumour volume, and presence of prostatitis. The Wilcoxon signed rank test
was used individually to test the significance of changes from Plasma Specimen 1
(the baseline) to each of the other three specimens. Each of these individual
comparisons was also tested based on groups using the Kruskall-Wallis test.

Results
All events in the 100-1000 nm size range, fluorescent or non-fluorescent, were
considered as the “total microparticle count”. This total MP count showed a
characteristic pattern that was consistent between participants (Figure 6). Firstly, the
total MPs from the intraoperative bloods (specimens 1-3) were all significantly lower
than the MPs in the follow-up sample (specimen 4) (p<0.001). Median MPs were 2
610 600 for all intraoperative samples versus 3 951 400 for post-operative samples.
Venous samples from healthy volunteers showed numbers of MPs per µl similar to
that of Specimen 4. Secondly, among the intraoperative specimens, there was a
consistent drop in total MP counts from Specimen 1 to 2, and again from 2 to 3
(Figure 6). Median total MP counts for specimens 1, 2, and 3 were 3 005 500, 1 600
600, and 976 353, respectively. This represented drops from baseline of 46.7% and
67.5%, respectively. The difference between the MP counts from specimen 1
(median 3 005 500), which were the highest of the intraoperative samples, and MP
counts from specimen 4 (median 3 951 400) approached statistical significance
(p=0.079).
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1 = Pre-DRE; 2 = Post-DRE; 3 = Post-prostatectomy; 4 = Follow-up

Figure 6: Total MP counts by specimen.

When considering only the fluorescent events, i.e. the PSMA, polysialic acid, and
dual positive MPs, there was an increase in median number of events progressively
from specimen 1 through to specimen 4 (Figure 7). This increase in absolute
numbers occurred in the intraoperative specimens despite the reduction in overall
MP levels. The increase was more pronounced for the dual positives (p=0.054 for
Sp1 vs Sp2 and p=0.016 for Sp1 vs Sp3). The positive MPs in specimen 4 were higher
than in specimen 1, significantly so with PSMA and dual positives (p=0.006 and
p=0.013), and approaching significance for polysialic acid (p=0.058).

(1 = Pre-DRE; 2 = Post-DRE; 3 = Post-prostatectomy; 4 = Follow-up)

Figure 7: Absolute PCMP counts by specimen number and MP population.
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The most dramatic differences were seen when comparing the positive MPs as
percentages of the total MP counts in each specimen (Figure 8). For example,
proportional dual positive values increased from a median of 9.6% in specimen 1 to
17.3% in specimen 2 (p<0.001), and then increased again to 25.7% in specimen 3
(p<0.001). The relative number of dual positive MPs dropped back down to 4.1%
post-operatively (p=0.170). The differences between the intraoperative specimens
were all highly statistically significant. The median postoperative proportional
positive values were all lower than at baseline, but those values were not statistically
significant.

(1 = Pre-DRE; 2 = Post-DRE; 3 = Post-prostatectomy; 4 = Follow-up)

Figure 8: Proportional PCMP counts by specimen number and MP population.

The data were interrogated to determine whether various clinical factors had any
impact on either baseline PCMP levels or change from baseline after DRE,
immediately after prostatectomy, or at follow-up after surgery. Participants were
categorised dichotomously on histological grade (ISUP grade group 1-2 vs 3-5), total
prostate volume (<40 g vs >40 g), tumour volume (<6 g vs >6 g), and presence or
absence of prostatitis on postoperative pathology. There were no significant
differences in any absolute MP counts or proportional values based on these
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categories. There was also no difference in levels of PCMPs or change from baseline
between men who had follow-up bloods taken at 3 weeks versus 3 months.
Within individual specimens, the values of PSMA, polysialic acid, and dual positives
were closely correlated, and one marker did not obviously perform particularly
better than the other. The combination of the two also did not give appreciably
different readings compared to the baseline.
Specimen 1
Microparticle count
(events/µl)
PSMA count
(events/µl)
Polysialic acid count
(events/µl)
Dual positive count
(events/µl)

%PSMA

%Polysialic acid

%Dual positive

Specimen 2

3 005 500

Specimen 3

1 600 600
6

(1,534 – 5,564 x10 )

293 881

976 353
6

295 002
(0.214 – 0.332 x10 )

268 314

(2.532 – 12.28 x10 )

p=0.016

p<0.001

p=0.079

298 244
6

(0.181 – 0.293 x10 )

303 807
6

6

(0.254 – 0.334 x10 )

(0.248 – 0.328 x10 )

(0.248 – 0.397 x10 )

p=0.170

p=0.058

p=0.013)

305 930
6

330 030
6

6

(0.243 – 0.356 x10 )

(0.244 – 0.339 x10 )

(0.199 – 0.430 x10 )

p=0.092

p=0.211

p=0.058

276 664
6

6

(0.708 – 1.476 x10 )

302 854
6

3 951 400
6

(0.964 – 4.218 x10 )

291 400
6

(0.217 – 0.324 x10 )

Specimen 4

283 443
6

295 013
6

6

(0.234 – 0.311 x10 )

(0.206 – 0.316 x10 )

(0.178 – 0.394 x10 )

p=0.054

p=0.016

p=0.006

10.9%

19.6%

28.1%

5.5%

(4.6% – 18.2%)

(7.5 – 29.8%)

(19.8 – 42.2%)

(2.4 – 15.7%)

p=0.001

p<0.001

p=0.099

11.3%

17.7%

26.9%

5.7%

(4.1 – 15.5%)

(5.9 – 26.2%)

(16.8 – 40.2%)

(1.7 – 16.0%)

p<0.001

p<0.001

p=0.181

9.6%

17.3%

25.7%

4.1%

(3.3 – 15.2%)

(5.4 – 24.3%)

(14.0 – 38.3%)

(1.7 – 14.7%)

p<0.001)

p<0.001

p=0.170

Table 3: Median values of total, # positive (events/µl), and % positive MPs (p-values denoting significance of
changes relative to specimen 1). Inter-quartile ranges in parentheses.

The discrepancy of reduced numbers of total MPs from the intraoperative arterial
blood samples compared to the postoperative venous blood samples was not
expected. In order to explore whether these differences were due to a global drop of
MPs or the reduction of a specific population of MPs, the plasma samples from
seven patients were analysed for CD41a and CD31 positivity. These markers are
specific for platelet and endothelial EVs, respectively.
While it appeared that there might be an increase in platelet MPs during surgery,
these results were not statistically significant (p=0.323).
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Figure 9: Absolute CD41a and CD31 positive microparticles.

Figure 10: Proportional CD41a and CD31 positive microparticles

See chapter 5 for discussion of these results.
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Chapter 4: Urinary Prostate Cancer Microparticles in
Men with Prostate Cancer
Background and Rationale
The prostate gland is an exocrine gland with a number of secretory products that
contribute to the ejaculate. Specialised extracellular vesicles, sometimes called
prostasomes, are secreted by the normal prostate. These subcellular structures have
several physiological functions in the semen, including support of the spermatozoa
and modulation of the female immune response to the sperm. They have been
detected in the plasma, and plasma levels have been found to be increased in
prostate cancer (PCa). Studies analysing urinary prostate EVs have shown potential
for diagnosis and risk stratification of PCa. Most of these studies have characterised
the contents of urinary EVs, such as miRNA or proteins. We are unaware of any
biomarker studies that have used flow cytometry to enumerate urinary prostate EVs.
Prostasomes are secreted directly into the urinary tract, and collection of urine is
less invasive than collecting blood, which together make the urine an appealing
potential substrate for the detection of PCa-specific MPs. Detection, enumeration,
and characterisation of PMP populations using flow cytometry in conjunction with
markers specific for prostate cancer has potential to be a totally non-invasive test for
prostate cancer.
A DRE is required prior to PCA3 testing because it increases the urinary
concentrations of the PCA3 mRNA. If MPs are detectible in the urine by flow
cytometry, then it is also plausible that a DRE would similarly improve urinary
concentrations of these MPs and increase the accuracy of a test based on MP
quantification.

Aims and Objectives
The primary objective of this component of the study was to determine whether
urinary prostate cancer microparticles (PCMPs) could be detected in the urine of
men known to have prostate cancer (PCa).
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Secondary objectives were to determine whether PCMP counts in the urine are
affected by DRE, or whether pre- or post-DRE urinary PCMP counts correlated with
clinical factors such as prostate volume, tumour grade, or tumour volume. The
working hypothesis was that digital rectal examination (DRE) would increase the
levels of urinary PCMPs in men with PCa.
A highly accurate urine test for PCa would be of great benefit in the field of urologic
oncology.

Materials and Methods
Study Design: The study was prospectively planned and the protocol was approved
by the institutional research ethics board of Western University (REB #107043). The
study was designed and carried out in accordance with local ethics regulations, as
well as with the Declaration of Helsinki.
Participants: All patients who were booked for robotic prostatectomy at an
academic referral centre (London, Ontario) were approached for participation in the
study. There were no further inclusion or exclusion criteria. Twenty-two (22)
potential participants were eligible for the study and were approached. All men
agreed to participate in the study. The analysis of urine for prostate MPs was an
exploratory component of the DRE study and not the primary objective. Therefore,
sample size determination did not take anticipated urinary MP levels into account.
Sample Collection Protocol: Study ID numbers were assigned sequentially as
DRE001 to DRE022, in order to immediately de-identify specimens and case report
forms. An encrypted master list was kept behind the hospital firewall. Each
participant had two urine sample taken as part of the study. Each participant was
asked to give a voided sample during the pre-operative preparation. The participant
was requested to give at least 40-50 ml, and to include the initial voided urine
component (rather than midstream urine). Those who were unable to pass a voided
sample immediately pre-operatively had an in-out catheterisation performed
immediately after induction of anaesthesia. The first urine specimen was labelled
“Urine Specimen A”.
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A vigorous digital rectal examination (DRE) was then performed for 2 minutes, with
firm pressure anteriorly, and sequential strokes from lateral to medial on alternating
sides. This DRE was followed by routine surgical preparation and sterile draping. The
second urine specimen was collected on insertion of the transurethral catheter prior
to starting the surgical procedure.
The samples were then centrifuged at 3000 g for 15 minutes. Supernatant was
aliquoted into ±10 labelled cryo tubes, each containing 1.5 ml urine. Samples were
then stored at -80°C.
Satisfactory urine samples were obtained for all 22 participants.
Specimen Testing Protocol: See Chapter 1 for more complete details on sample
handling, antibody preparation, flow cytometer settings, and antibody optimisation.
Since the analysis of urine in the DRE study was the exploratory component of the
study, the testing protocol was changed with serial experiments. Running of patient
and healthy volunteer urine supernatant without antibody showed that there were
10-20 fold fewer events in the 100-1000 nm size range than in human plasma.
Initial experiments used an exact duplication of the protocol used for plasma, with
10 µl of urine supernatant with 2 µl of the anti-PSMA and anti-polysialic acid
antibodies. However, because of the very low density of MPs, the presumed positive
signals in the 10 µl sample were lost when diluting with 290 µl of PBS. An alternative
strategy attempted was to use a greater volume of urine, up to 300 µl, to stain with
antibody and run undiluted. The large volume of urine with such a small quantity of
antibody also did not seem optimal for antibody binding. In these experiments, the
active antibody produced similar populations to the isotype control, presumably
from non-specific binding.
Much higher concentrations of urinary MPs were achieved using ultracentrifugation
of urine. Comparative analysis of the pellets and supernatant from ultracentrifuged
samples confirmed significant concentration of MPs. The protocol that was
developed and used to test the entire cohort was as follows:
Separate samples of 1,000 µl of urine were centrifuged at 14,000 G for 45 minutes.
950 µl of supernatant was carefully removed from the surface of the specimen and
the pellet resuspended in the remaining 50 µl of supernatant. 10 µl of resuspended
centrifuged urine was pipetted into a new centrifuge tube. Antibody was carefully

62
pipetted into the urine and mixed thoroughly by gentle backwards and forwards
pipetting. 0.75 µg of anti-PSMA-3E7-PE (2 µl @ 0.375 mg/ml) and 0.8 µg of antipolysialic-acid-FITC (2 µl @ 0.4 mg/ml) were used.
Specimens were mixed with a vortex mixer and then spun down in a low velocity
benchtop centrifuge. They were then incubated in the dark for thirty minutes. After
incubation, urine samples were diluted with sterile phosphate-buffered saline (PBS)
to a volume of 300 µl. Isotype controls were performed on several of the urine
samples to exclude non-specific staining. Since non-specific binding did not seem to
be a problem at any point, with ROI gates being predominantly clear , we did not
perform isotype controls on all samples.
Samples were then analysed using an Apogee A50 nanoscale flow cytometer. Laser
thresholds were set above the level of approximately 100 nm size, based on silica
bead calibration, to reduce noise levels. Events in the two different spectra (orange
for PSMA-PE and green for Polysialic acid-FITC) were enumerated using wide gating
logic to capture all potential multiple positives. Single and dual positive MP
concentrations were enumerated (as events/µl). Total event events and total events
per µl were also recorded. Using the total MP counts per specimen as a
denominator, proportional single and dual positive events were calculated and
recorded.
Similar to the plasma samples run, each sample generated 7 data points for
statistical purposes. Those were: Total MPs, absolute PSMA, absolute polysialic acid,
absolute dual positives, proportional PSMA, proportional polysialic acid, and
proportional dual positives.
Statistical Analysis: Data was entered onto a spreadsheet using Microsoft Excel
2010. Statistical analysis was performed using IBM SPSS version 23.
Variables were tested for normality using the Shapiro-Wilk test. Since almost all of
the variables were not from normal distributions, non-parametric statistical tests
were used for the analysis. For testing the significance of differences between the
pre-DRE and post-DRE urine samples, the Wilcoxon signed rank was used. The MannWhitney U test was used to test for significant differences between pre- and postDRE samples in relation to dichotomous categorical differences, namely as
histological grade, prostate volume, and tumour volume.
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Patient Characteristics: 22 men were enrolled in the study between October 2016
and April 2017. See the “materials and methods” section in chapter 3 and the
accompanying Table 2 for a complete description of the cohort.

Results
Comparison of ultracentrifuged urine pellets from specimens A and B showed that
the total MP counts differed significantly (Table 4). Median events per µl were 667
453 before DRE and 2 793 500 after DRE. This difference was highly significant
(p=0.001).

Total MPs
Specimen A – Pre-DRE

Specimen B – Post-DRE

p-value

PSMA

Polysia

Dual

% PSMA

% Polysia

% Dual

667 453

28 165

12 837

11 876

3.946%

1.574%

1.321%

(416 323 –

(14 472 –

(4 220 –

(3 875 –

(1.629 –

(0.667 –

(0.485 –

1 357 350)

45 226)

31 421)

24 271)

8.391%)

4.060%)

3.686%)

2 793 500

28984

16141

12780

0.864%

0.884%

0.321%

(1 231 125 –

(14 228 –

(5 591 –

(4 436 –

(0.347 –

(0.238-

(0.196-

7 107 925)

45 602)

36 852)

23 834)

2.007%)

1.470%)

0.944%)

0.001

0.907

0.489

0.907

0.002

0.037

0.011

Table 4: Median values of total, # positive (events/µl), and % positive urinary MPs (p-values for difference
from Spec A to Spec C). Inter-quartile ranges in parentheses.

Figure 11: Total urinary microparticle counts before and after DRE.
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The numbers of MPs positive for PSMA and polysialic acid, as well as the dual
positives, were very similar between specimen A and B. None of the differences
were statistically significant (Figure 12).

Figure 12: Absolute positive urinary microparticles before and after DRE.

As a result of the large discrepancy in the numbers of absolute MPs with the static
numbers of positives, the proportional numbers of positive MPs were all significantly
lower post-DRE (Figure 13).

Figure 13: Proportional positive urinary microparticles before and after DRE.
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Chapter 5: Discussion
Plasma Microparticles
All of intraoperative total MP counts were significantly lower than the postoperative venous blood draw. This phenomenon was first observed when analysing
plasma samples from the first two patients after their three week follow-up. The
immediate concern was that there had been a drop in the stored plasma samples,
since they were three weeks older and had up to that stage been stored at -20°C.
Subsequent experimentation in the laboratory (not discussed here) as well as the
subsequent experience with the remainder of the cohort reassured us that this was
not the case. One potential explanation is that these samples were arterial and
venous blood, respectively, and that the difference we saw is truly representative of
true in vivo physiology. There were no studies identified in the literature review that
compare EV concentrations in arterial versus venous blood. Some studies examining
EV clearance in vivo have shown that they have half very short half-lives in the
circulation, as little as 2 minutes, and are found up to several hours later
sequestered in the spleen, liver, and lymph nodes (185–187). These findings,
combined with the findings that EVs are stable in non-circulating blood, suggest that
they are cleared by the reticuloendothelial system (RES). Other studies have shown
longer half-lives, up to 5.8 hours, and that EVs expressing different surface markers
might be preferentially captured within the RES. Also, none have mentioned whether
lung tissue was examined, which would most easily account for the very short halflife and the discrepancy between arterial and venous blood.
In addition to the differences in total MP counts between the intra- and postoperative specimens, this study found that total MP counts dropped from the first
time-point a few minutes after induction of anaesthesia, to the second time-point,
usually about 10 minutes later. The levels were consistently further decreased in the
third specimen, taken two to three hours after the first two samples. This
phenomenon is also not explained. It is quite possible that the underlying cause of
this progressive decline is the same as for the low levels among the intra-operative
specimens as a whole. The participants were all under anaesthesia, and there was
therefore an inverse correlation between total MP counts and duration under
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anaesthesia. MP levels may have been influenced by intravenous fluid
administration, the subcutaneous heparin given at induction, or other drugs such as
the volatile agents, propofol, opioids, or antibiotics. Explanations related to
procedural error in sample processing, such as time to processing, also do not
account for the difference. Sample processing took place either twice during a case
(specimen 1 and 2 together, then specimen 3 later), or once all together at the end
of the case. The pattern of MP decrease persisted despite the procedure followed.
When processing was done at two time points, the third specimen’s MPs were still
appreciably lower. When processed all together (4-5 hours after the beginning of the
case), there was still a large discrepancy between specimens 1 and 2, taken only 10
minutes apart.
Another uncertainty was whether the changes in overall MP concentrations were
the result of all MPs in the specimen being reduced from baseline, or if there was a
selective reduction of one or more specific populations within the blood. It is
possible that the heparin given at induction of anaesthesia might cause a progressive
reduction in platelet-derived MPs. Another possibility is that a venous blood draw,
where slow-moving blood is sampled that has already moved past the needle’s point
of entry into the vein, could contain a significant number of MPs derived from
endothelial trauma and platelet activation. Conversely, arterial blood is taken from a
cannula that points towards a much more rapid flow of blood, which would make
these samples much less likely to be influenced by the local vascular trauma. To test
these hypotheses, a previously optimised pair of antibodies against CD41a and CD31
was used to examine seven sets of patient plasmas. These markers are specific for
platelet and endothelial cell MPs, respectively (157). It was found that neither MP
population mirrored the total MP population, indicating that isolated differences in
either of these MP populations were not the cause of the overall differences in MP
counts that were seen. Unfortunately, limitations to time and antibody precluded
examination of the whole cohort. Concerns about the validity of this protocol were
that the antibody concentrations used were extremely low, and positive populations
for platelets and endothelial MPs were both less than 1% of total MP counts, when
they would be expected to account for >70% and >10% respectively.
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The effects of fasting might also have influenced total MP levels. All men were
fasted for at least 6 hours prior to surgery, but many would not have had food since
the evening before. Additionally, it might be assumed that most men were not
similarly starved at their follow-up appointments. If these assumptions were true
then there would be a negative correlation between total MPs and duration of
fasting. The effect of fasting on EV concentrations is not known (188), but it is
possible that a reduction in small chylomicrons in the 100-1000 nm size range might
account for the observed discrepancy. This explanation, however does not account
for the significant difference in MP levels between Specimens 1 and 2, taken only 10
minutes apart.
Looking at the MP populations positive for PSMA, polysialic acid, and both, the
concentrations of all remained fairly stable, despite the differences in overall MP
concentration. The only consistent significant differences were between baseline
(specimen 1) and follow-up (specimen 4), where the absolute positive MPs actually
rose. The higher PMP levels in these men is difficult to explain, considering their lack
of prostates, and presumably in most cases, prostate cancer. If the assumption is
made that whatever accounted for the large differences in total MP counts between
specimens also affected all MP populations equally, then it would be rational to
consider the concentration of positive MPs as a proportion of the concentration of
total MPs. If one does this, then the changes in the relative PMP confirm the
hypothesis of the study very well. Relative PMP levels increase significantly after a
DRE, then increase significantly further over the duration of surgery, and then drop
back down to a level below baseline at follow-up (although the latter change not
being statistically significant). There was no difference between PMP levels at 3
weeks and at 3 months.
None of the secondary objectives of the study, related to plasma analysis, achieved
statistical significance – most likely because of low power from the small numbers of
participants. Gleason score, prostate volume, or tumour volume did not correlate
with PSMA, polysialic acid, or dual positive MP levels.
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Urine Microparticles
Analysis of patient urine samples generated large numbers of positive events,
which likely represent MPs derived from the prostate gland.
Wide variations in event counts were noted between different patients, which was
most likely due to differing urinary concentrations. Also, some of the participants
had significant amounts of debris in their urine samples, which may have contributed
“nano-debris” to samples, and accounting for the increases in non-specific MPs.
There were significantly more total microparticles in post-DRE urine, which was
either the result of the DRE itself, or the catheterisations used to retrieve the second
(and sometimes the first) urine samples. A set volume of first-void urine should
ideally have been used for both pre- and post-DRE urine samples to optimally catch
the prostatic secretions. Unfortunately, the design of this study precluded such a
collection method.
In the context of a urine biomarker, normal variation in urine concentration would
make absolute concentrations an unreliable continuous variable for diagnosis or risk
stratification. Having to ultracentrifuge small quantities of urine would also
introduce room for error. Urine tests for PCA3 or TMPRSS:ERG RNA also measure the
concentration of PSA mRNA. This serves several important purposes: It tests whether
the urine specimen is adequate for analysis and it serves as a denominator to allow
the PCA3 or T2 to be reported as a ratio. This latter function is most important, since
a baseline PSA mRNA concentration is relatively reliable and predictable, so it
compensates for differing concentrations of urine and prostate secretions in the
sample (37). The MP analysis in the DRE study lacked such a “control”, which was a
shortcoming in the study design. Duijvesz et al. have reported using urinary PSA and
protein concentrations as a baseline for urinary MP quantification (154) . Many
blood and tissue RNA tests use a similar baseline by testing for “housekeeper” genes
that are known to be expressed in all cell types at a predictable level.
The small number of participants in our study made it impossible to correlate
findings of MP concentrations with clinical factors, such as PSA, histological grade,
tumour volume, or prostate volume.
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Challenges and Shortcomings
The original study design specified a triple test, that included STEAP1 along with the
PSMA and polysialic acid. Unfortunately, the STEAP1 antibody that was available
from two different suppliers did not reliably produce MP populations the study
samples. This problem could not be resolved during the study period, and the final
analysis of the samples therefore needed to be performed using only two antibodies.
Work done by other investigators in the Leong laboratory suggests that elimination
of the anti-STEAP1 from the protocol would reduce the specificity of the test by a
small amount. Although this was less than desirable, the study compared changes in
MP counts within the same participants, so the omission might not have impacted
on the primary outcome of the study, which was determining the change in
concentration with DRE. However, performing a dual instead of a triple antibody test
could have reduced the ability to detect differences between subgroups of
participants, such as histological grade or tumour volume. It is more likely that the
study would still have been underpowered for these secondary outcomes.
The many processes in the protocol of the DRE study were made up of many
individual steps that all had to be tightly controlled to reduce error as much as
possible. Preparation of samples for analysis, for example, involved pipetting
multiple small volumes, each prone to error. Much of the protocol had to be
developed during the study. Decisions on standardising certain aspects were based
as far as possible on experimentation (such as optimisation of antibody
concentration and volume used), but several decisions were sometimes fairly
arbitrary, with little data in the literature to guide decisions. It is not known whether
these impacted negatively on the study. Examples of these include the freezing and
thawing of specimens, whether or not to use cryo-protectants, the volume of plasma
to use for each sample tested, and many of the calibration settings on the flow
cytometer.
For all of the antibodies used during the study, there was the potential for batch to
batch variation in antibody characteristics. This proved to be a critical problem for
STEAP 1, but there was likely some variation with the other antibodies. There could
also have been variation in the conjugation reactions, as well as degeneration of the
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antibodies and fluorophores during storage. To circumvent this, the whole cohort of
samples was re-run close to the end of the study period using the same batches of
PSMA and polysialic acid antibodies. While this strategy would have produced more
reliable results, it might also limit the reproducibility of the study.
Including a cohort of men without prostate cancer, such as men undergoing other
urological surgery, might have allowed determination of the degree to which MPs
were increased due to prostate cancer versus benign prostate tissue. Such a followup study would be a logical next step.
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Conclusions
This study demonstrated that total plasma microparticle concentrations were
significantly lower in plasma samples taken from arterial lines of men under
anaesthesia than in venous blood taken from the same men at follow-up. Whether
this difference was due to the arterial nature of the intraoperative specimens, or
some factor related to the anaesthesia itself, is uncertain. It is also not certain
whether the reduced microparticle concentrations represent a global reduction in
plasma MPs or if it represents a reduction of a particular MP subpopulation.
Microparticles that express PSMA and polysialic acid can be successfully labeled
using ligand specific antibodies conjugated to fluorophores, and these MPs can then
be detected using nano-scale flow cytometry. Expression of both of these cell
surface markers is known to be increased in prostate cancer, and work done in our
laboratory has shown that the presence of these MPs is sensitive and specific for
prostate cancer. The proportion of MPs per specimen that are positive for these
markers increases significantly following a two minute vigourous digital rectal
examination, and further increases three to four hours after the DRE, and once the
prostate has been removed. Proportional levels then decrease to a level at or below
the pre-operative level after a period of at least three weeks.
Prostate microparticles can also be detected in the urine after ultracentrifugation
and a similar process of antibody labeling and flow cytometry. The concentration of
these microparticles does not seem to be significantly increased following DRE,
although a shortcoming of the study might be that catheter specimens were taken
instead of first voided specimens. Catheterisation did seem to increase the total
numbers of MPs, presumably due to disruption of the mucosa.
Further studies are necessary to properly understand the differences between MP
concentrations in arterial versus venous blood, the effects of anaesthesia on MP
concentrations, as well as the lifespan and metabolism of MPs. When viable MPbased tests for prostate cancer become available, it will be important to determine
whether a DRE prior to blood sampling could increase the accuracy of those tests,
since there is now some evidence to suggest that plasma prostate MP numbers are
proportionally increased after DRE. Enumeration of prostate MPs in the urine is also
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a promising potential test for PCa. With a formal protocol involving
ultracentrifugation of specimens prior to analysis, these can be reliably detected
with fluorescent antibodies and flow cytometry. There is sometimes wide variation
in total microparticle concentration in both plasma and urine. Quantification of
organ-specific MPs would therefore be more useful if there was a reliable
background MP population against which to compare. Further work in this direction
is also needed.
Prostate-specific MP quantification is a promising biomarker for the presence of
prostate cancer, as well as a potential indicator of disease severity. Future studies
should be performed toward developing and validating quantitative PMP
measurement as a biomarker for prostate cancer. In that setting, pre-test DRE
should be considered to increase circulating PMP concentrations, and to determine
whether concentrations are similarly increased in men without prostate cancer.
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Appendices
Appendix 1: Glossary of Terms


Extracellular vesicle (EV) – Subcellular phospholipid-bound particle, originating
from a cell, between 30-1000 nm in diameter.



Microparticle (MP) – Interchangeable term with “Ectosome”. EV originating from
the outer plasma membrane of a cell by a process of membrane budding.
Generally 100-1000 nm in diameter.



Exosome – EV arising from a process of exocytosis from MVB. Generally 30-100
nm in diameter.



Endosome – Not an EV. Membrane-bound structure within the cytoplasm
resulting from endocytosis.



Multivesicular body (MVB) – Membrane-bound structure within cytoplasm,
containing multiple intraluminal vesicles (ILVs). Fuses with the outer cell
membrane to release the ILVs as exosomes.



Apoptotic body – EV produced as a result of apoptosis, which are fragments of
the apoptotic cell. These are easily phagocytosed by phagocytes, and thereby
prevent an immune response.



Flow cytometry – a process to analyse the particulate components of a fluid by
passes a stream through a narrow channel and measuring either electrical
impedance or scattered laser light.



Prostate-specific membrane antigen (PSMA) – transmembrane protein found
mostly in glandular cells of the prostate that is involved in folate metabolism.



Six-transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) –
transmembrane protein located primarily in prostatic glandular cells, responsible
for reduction of metals such as iron, copper, and zinc.



Polysialic acid – a complex carbohydrate post-translational modification of the
neural cell adhesion molecule (NCAM), which is important for growth and
development, cell-cell adhesion, and neural regulation. Overexpressed in many
malignant cell lines.
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Radical prostatectomy – a treatment for prostate cancer with curative intent,
that is surgical removal of the entire prostate, its fascial coverings, and usually
the seminal vesicles.



Phycoerythrin – a fluorophore derived from red algae, with peak absorption at
565 nm, peak emission at 575 nm, and a high extinction coefficient of 1.96 x 106
M−1cm−1.



Fluorescein isothiocyanate – commonly used fluorophore with peak absorption
at 494 nm, peak emission at 521 nm, and extinction coefficient of 9.24 x 104 M1

cm-1 at a pH of 7.
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Appendix 2: Ethics Approval Notifications
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Appendix 3: Case Report Form for DRE Study
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Appendix 4: Letter of Information for DRE Study

Letter of Information
Yield of Prostate Cancer Microparticles After Digital Rectal Examination of Prostate
Cancer Patients.
Principal Investigator: Hon Leong
You have been scheduled for radical prostatectomy of the prostate gland. All patients who are scheduled for this
procedure are eligible to participate in this research study. We invite you to participate in this study. Our ultimate
goal is to clinically validate a blood test (fluid biopsy) to improve diagnosis and prognostication of prostate cancer.
Please read the following information carefully and discuss it with your family and/or family doctor, if you wish. If
you wish to participate, you will be asked to sign the consent form.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed malignancy in males in Canada. We have developed a
blood test that enumerates prostate cancer cell fragments released by the tumor into the bloodstream. We have
previously shown that this blood test can distinguish low risk prostate cancer patients from high risk prostate
cancer patients. To improve the efficacy of this blood test, digital rectal examination (DRE) may cause increased
blood levels of prostate cancer cell fragments (also known as prostate cancer microparticles) or a raised blood test
called PSA (Prostate Specific Antigen) and to confirm the diagnosis, a biopsy is mandatory. However, DRE and
PSA test are not specific for the prostate cancer. Currently, 75% of men with high PSA levels do not have PCa
according to their biopsy. If we are able to refine our criteria for biopsy we will be able to avoid unnecessary
biopsies of the prostate.
Prostate cancer fragments, also known as microparticles are present in the blood of prostate cancer patients in a
very small quantity. This is an emerging topic in oncological research. Our laboratory has developed the capacity
to measures prostate cancer fragments in the blood. This test may be better than the PSA test which may be
raised in both benign prostatic hyperplasia (BPH) and PCa patients. The blood test for prostate cancer
microparticles may prevent a large majority of men from being submitted to unnecessary prostate biopsy.
The focus of this work is to validate the clinical utility of our prostate cancer microparticle test as a screening tool
and to compare its accuracy with PSA test.
Study Procedures
If you agree to participate we may collect demographic data including date of birth and the pre-biopsy PSA results.
We will ask you to provide us with a urine sample before going into the OR. While you are under anesthesia you
will have three 8 ml tubes of blood drawn by the surgeon as well as 10 ml of urine collected by the surgeon. At
three weeks to three months after the surgery, we will request one last tube of 8 ml blood drawn by a qualified
health care professional when you visit your urologist for your first follow-up visit. All blood and urine samples will
be analysed for the presence of prostate cancer microparticles and correlated with the biopsy report and your
follow-up PSA result.
Your ongoing care will be unchanged and will continue as usual in consultation with your urologist. We will be
enrolling 74 patients over the next year; all study participants will be patients of Dr. Stephen Pautler or Dr.
Nicholas Power. Please note that you will not receive the results of any of the tests that will be performed for
research purposes.
Initial: ________________________________
Page 1/3
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Potential Risks
There is no known major risk in participation except the minor discomfort of giving the blood during your first
followup visit. As veins may vary in size from one patient to another obtaining a blood sample from some people
may be more difficult than from others. Some patients may feel light-headed but fainting is extremely rare. There is
remote chance of forming a hematoma or infection.
Potential Benefits
The main benefit from this study is to patients in the future. We might be able to better select patients for prostate
biopsy.
Treatment Alternative(s)
This study will not alter your treatment other than the potential benefit of mentioned in the preceding section.
Funding:
None.
Confidentiality:
The information collected will be used for research purposes only, and neither your name nor information which
could identify you will be used in any publication or presentation of the study results. All information collected for
the study will be kept confidential; however, representatives of The University of Western Ontario Health Sciences
Research Ethics Board may contact you or require access to your study-related records to monitor the conduct of
the research. While we will do our best to protect your information there is no guarantee that we will be able to do
so. The inclusion of your initials and date of birth may allow someone to link this data to you.
Reimbursement:
There is no reimbursement for participation in this study.
Participation:
Participation in research is voluntary. If you choose to participate in this study you may withdraw at any time. If
you do not wish to participate, you do not have to provide any reason for your decision not to participate nor will
you lose the benefit of any medical care to which you are entitled to or are presently receiving. You do not waive
any of your legal rights by signing the consent form.
Questions about Database or Treatment
If you have any concerns in regards to the recording of your details or wish to withdraw from this study please
either mention this to your Urologist or alternatively contact:
Dr. Hon Leong, Division of Urology, Department of Surgery, 268 Grosvenor St., London, Ontario
Questions about Your Rights or This Studies Conduct
If you have any questions about your rights as a research participant or the conduct of the study you may
contact: Dr. David Hill, Scientific Director, Lawson Health Research Institute at (519) xxx-xxxx.
If you have any concerns regarding this study you can contact the Principal Investigator, Dr. Hon Leong at
519-xxx-xxxx or the Urology Research Office at 519-xxx-xxxx.
Initial: ________________________________
Page 2/3
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Consent for Participation
Study Title: Yield of Prostate Cancer Microparticles After Digital Rectal Examination of Prostate Cancer
Patients.
Principal Investigator

Hon Leong

I have read the letter of information, have had the nature if the study explained to me and all questions have been
answered to my satisfaction and I agree to participate
Name (please print)___________________________
Signature_______________________
Date_____________________
Person Obtaining Consent______________________
Signature_____________________
Date_______________________
Page 3/3
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Appendix 5: Curriculum Vitae
Name: Malcolm James Dewar
Undergraduate Medical Training
 Bachelor of Medicine and Bachelor of Surgery (MBChB) 1998-2003, University of
Cape Town, Cape Town, South Africa
Postgraduate Education and Training
 Registrar in General Surgery at the University of Cape Town – Nov 2008 to Jan
2012 (39 months)
 Registrar in Urology at the University of Cape Town – Feb 2012 to May 2016 (52
months)
 FCUrol(SA) – South African College of Urologists, Awarded May 2015.
 MMed(Urol) – University of Cape Town, Awarded December 2016
 SUO Fellow in Urologic Oncology – London Health Sciences Centre and Western
University, July 2016 to June 2018
 Enrolled in MSc (Surgery) programme – Western University, Sept 2016 to Aug
2017.
Related Work Experience
 Registrar in Urology - University of Cape Town, Cape Town, South Africa, Feb
2012 to May 2016
 SUO Fellow in Urologic Oncology – London Health Sciences Centre and Western
University, July 2016 to June 2018
Honours and Awards
 Phillip Smith Prize for the Best Post-Graduate Student in Urology, University of
Cape Town, 2015.
 Discovery Health Prize for the best paper/presentation by a South African
Urologist no longer in training at the SAUA biennial meeting, for the
presentation “Investigating racial differences in clinical and pathological
characteristics of prostate cancer in South African men” (Nov 2016).
Registrations and Affiliations
 Registered as a Urologist with the Health Professions Council of South Africa
 Registered as a Clinical Fellow with the College of Physicians and Surgeons of
Ontario
 Fellow of the South African College of Urologists
 Member of the South African Urological Association
 Member of the Society of Uro-Oncology
Publications
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